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INTRODUCTION 
1. INTRODUCTION  
 
1.1 Breast cancer - An overview 
 
1.1.1 Breast cancer facts and figures 
 
The global burden of cancer continues to increase mostly because of the aging, 
factors like exposure to UV radiation, pollution and a rise in the adoption of cancer-
causing behaviors (obesity, poor diet, smoking habits etc.). Breast cancer is the most 
frequently diagnosed cancer and the second leading cause of cancer death among 
females 1. Latest statistics estimated almost 230,480 new cases of the invasive 
breast cancer occurring among women during 2011 and about 2,140 new cases in 
men. For the year 2012, almost 39,970 deaths due to breast cancer are expected 
along with 226,870 new cases (Figure 1) 2.  
 
 
(Adapted from: Cancer Facts & Figures 2011, Atlanta: American Cancer Society, 2011, copyright 2012 by American 
cancer society inc., surveillance research) 
 
Figure 1. Statistical representation of cancer cases and deaths in the year 2012. Highlighted 
areas (Red bordered box) show number of breast cancer deaths and cases estimated in 2012 2. 
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1.1.2 Breast cancer development and types 
 
Almost 95% of the breast cancers arise from epithelial cells and hence are termed 
carcinomas 3. They can be classified in the following two major types: 
 
A. Non-invasive breast cancer. This category consists of cancer types that are 
localized to the ducts or the lobules. These are further characterized based on 
the location. The ductal carcinoma in situ (DCIS) is defined by a mass of 
proliferating cancer cells confined to ducts, with no evidence of invasion through 
the basement membrane 3. It is one of the prevalent types of breast cancer 
showing a dramatic increase in the number of cases since the year 1970. The 
second type of non-invasive carcinoma is lobular carcinoma in situ (LCIS) that 
arises and is confined to the milk producing glands or lobules. The proportion of 
LCIS in benign breast disease is low, ranging between 0.5% and 4%, but the 
majority of these lesions are multicentric, suggesting a more widespread process 
4.  
Furthermore, Paget’s disease of the nipple is the third type of non-invasive 
cancer which is a rare form of breast cancer, accounting for just 1% of all cases.  
 
B. Invasive breast cancer. This is the type of cancer that spreads outside the 
membrane of the lobule or duct into the breast tissue. Consequently, the cancer 
cells will either remain localized to the breast or metastasize to other parts of the 
body, such as lymph nodes in the armpit or beyond, to the brain, bones, liver, or 
lungs hence giving rise to metastatic breast cancer (MBC). Strikingly, about 80% 
of all breast cancers are invasive ductal carcinomas (IDC) spreading through the 
cells of the ducts. On the other hand, invasive lobular carcinoma (ILC) starts 
spreading through lobules. It accounts for only 10–14% of all breast carcinomas. 
Its incidence is greater than that of invasive cervical carcinoma 5. Furthermore, 
invasive breast carcinoma (IBC) is a form of rapidly progressive locally advanced 
breast cancer (approximately 3-5% of all breast cancers) characterized by 
discoloration ranging from red to purple and affecting at least one third of the 
breast, thickening and/or fine dimpling, warmth, and a palpable ridge present at 
the margin of indurations. 
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 1.1.3 Molecular classification of breast cancer 
 
Breast cancer is a heterogeneous disease, comprising of numerous distinct cell types 
having different biological features and clinical behavior. Therefore, classification of 
breast cancer cannot be limited to the one based on localization and the extent of the 
tumor. To further classify breast cancer on molecular basis, various groups utilizing 
different molecular techniques and comprehensive gene profiling analysis have 
revealed five major subtypes of breast cancer: basal-like, luminal A, luminal B, 
HER2+/ER–, and normal breast–like 6-9. Such molecular differences lead to distinct 
clinical outcomes and responses to treatment. Amongst the subtypes, luminal A-type 
tumors have the best prognosis and are low-grade tumors 8. On the other hand, 
luminal B type tumors are usually more aggressive demonstrating more proliferation 
and hence are high-grade tumors. Besides, basal-like tumors show relatively poor 
prognosis and express some molecules found in the basal/ myoepithelial 
compartment of normal breast tissue. These tumors are frequently negative for 
(Estrogen Receptor) ER and HER2 10. The better insight of the molecular subtypes of 
breast cancer eases the choice of therapy regimen for the patients and ensures more 
sensitivity to the treatment. Besides, molecular heterogeneity as described in this 
section forms the basis of this thesis in characterizing chemoresistance mechanisms. 
  
1.2 Regular treatment options 
 
In the recent years, life-saving treatment strategies for breast cancer advanced 
dramatically bringing new hope and excitement. Instead of just one or two, various 
treatment options are available for breast cancer. Furthermore, a choice of treatment 
based on the factors like age, physiological condition of patients and stage of cancer 
is possible. Treatment options for the breast cancer could be characterized as follows 
 
1.2.1 Local treatment options 
 
This type of treatment specifically targets the tumor and rest of the body parts 
remains unaffected. It constitutes the following procedures. 
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A. Surgery. Surgical removal is suggested to patients having a localized tumor below 
4 cm. Lumpectomy is a type of surgery referring to surgical removal of the tumor 
in breast along with negligible amount of surrounding tissue. Another version, 
partial mastectomy is extensive and removes more amount of normal tissue 
surrounding the tumor. This is also referred to as quadrantectomy. These two 
surgical procedures constitute the ‘breast conserving surgery’ as the removal of 
complete breast is avoided. Furthermore, patients with a more advanced stage of 
breast cancer may undergo a total mastectomy or complete removal of breast 
with a sentinel lymph node biopsy. For a more advanced tumor radical 
mastectomy is advised that includes removal of breasts along with removal of 
lymph nodes in the armpits and chest. Surgeries are the preferred mode of 
treating breast cancer when accompanied with radiotherapy or chemotherapy.  
 
B. Radiation therapy. Surgical removal of tumor is often followed by radiation 
therapy to remove residual microscopic cells 11. Superiority of this combination 
can be proved by data demonstrating a recurrence rate of 14.3% for those 
patients undergoing breast conservation therapy followed by radiation as 
compared to 39.2% for those undergoing surgery alone 12.  
 
1.2.2 Systemic treatment options 
 
Molecular classification of breast cancer has made it possible to administer specific 
enzymes, drugs, antibodies and hormones for treating cancer. When these 
compounds are administered either through blood vessels or orally, it is 
characterized as systemic therapy. 
 
A. Chemotherapy. Chemotherapy is usually recommended for all women with an 
invasive breast cancer that is hormone receptor-negative. It is usually 
administered through blood steam or given orally. On the other hand, regional 
chemotherapy is the administration of drugs directly into the cerebrospinal fluid, 
an organ, or a body cavity such as the abdomen, mainly affecting cancer cells in 
those areas. Several therapeutic drug options are available for the treatment 
through chemotherapy and are discussed later in the introduction.  
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B. Hormone therapy. Hormone therapy removes hormones or blocks their action and 
stops cancer cells from growing. For example, hormone therapy with tamoxifen is 
often given to patients with early stages of breast cancer and those with 
metastatic breast cancer 13. Moreover, hormone therapy with an aromatase 
inhibitor is given to some postmenopausal women who have hormone-dependent 
breast cancer. 
 
C. Targeted therapies. Therapies targeting a specific downstream protein or a 
metabolite comes under this category and is being studied extensively. Figure 2 
summarizes all targeted drug possibilities established or under study.  Some of 
the frequently used therapeutic strategies are targeting HER2 and VEGF protein 
that play important role in tumor progression and chemoresistance. There are a 
lot of hopeful drug candidates used commonly for the targeted therapies now a 
day like bevacizumab (an anti-VEGF-A antibody), everolimus (an inhibitor of 
mTOR), sunitinib and sorafenib (multitarget drugs) 14. Furthermore, lapatinib 
(HER1 and HER2 dual inhibitor), pertuzumab, trastuzumab-DM1 and neratinib 
constitute promising drugs/ antibodies used for targeting HER2. In addition to 
these drugs, many others drugs have been developed or are being developed 
that target hallmarks of cancer specifically e.g. sustaining proliferative signaling, 
avoiding immune destruction, activating invasion and metastasis, resisting cell 
death and so on 15.  
 
1.2.3 Common adjuvant chemotherapy regimens 
 
Cancer treatment is often a combination of different types of therapies to ensure 
eradication of the entire tumor. Likewise, chemotherapeutics are administered in 
combination for better effect and treatment. AC/TAC (adriamycin and 
cyclophosphamide/ taxol, adriamycin (doxorubicin) and cyclophosphamide), 
CMF/CAF (cyclophosphamide, methotrexate and fluorouracil/ cyclophosphamide, 
adriamycin and fluorouracil), EC/CEF (epirubicin and cyclophosphamide/ 
cyclophosphamide, epirubicin and fluorouracil) and TC/TCH (taxotere and 
cyclophosphamide/ taxotere, cyclophosphamide and herceptin) are the examples of 
some combinations frequently used in clinics.  These combinations reach response 
rates from 60% to 100% when administered in a primary or adjuvant setting 12,16. In 
INTRODUCTION 
spite of this fact, in about 40% of the breast cancer cases a relapse is seen 
accompanied by a decline in chemotherapy response rates to only 20% 17. 
 
 
(Adapted from: Hallmarks of cancer: the next generation, Hanahan D, Cell, 2011, 144(5), p 668, copyright 2011 by 
Elsevier inc.) 
 
Figure 2. Targeting hallmarks of cancer for therapy. Summary of all the possible therapeutic target 
proteins/metabolites opening up new therapeutic field for cancer. Some of these targeted therapies 
are already being used and others are understudy or clinical trials 15.  
  
 
1.2.4 Chemotherapeutics and their mode of action 
 
One of the hallmarks of cancer is high proliferation of cells. Therefore, targeting 
proliferation is one of the logical approaches towards treatment. The drugs targeting 
genetic material of the cells and hence proliferation, come under category of DNA 
altering agents. DNA alkylators or cross-linkers (platinum-based drugs) form major 
part of this category 18. Cisplatin is the most effective drug that is in the clinical use 
since 1972 to treat a variety of cancer types 19. All alkylating agents form covalent 
linkages with macromolecules having nucleophilic centre. As the end result of this 
treatment DNA replication is blocked that in turn may discontinue RNA replication 
and protein synthesis 20.  
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Furthermore, anthracyclin drugs are also frequently utilized drugs termed antitumor 
metabolites. Doxorubicin and daunorubicin are among the most important drugs from 
this category in terms of the clinical activity 21. Anthracyclins intercalates in the major 
groove between the base pairs of the DNA double helix and RNA that in turn leads to 
interference with the DNA replication, RNA transcription, translation, and inhibition of 
enzyme activities and proper membrane functioning. Likewise, epirubicin (adriamycin 
analogue) and Mitoxantrone (anthracenedione antibiotic) are used in combination 
with other drugs and can replace anthracyclines 22,23.  
Additionally, antimetabolites have been in use for the treatment of the malignant 
disease for 50 years, since their discovery 24. These drugs interfere with normal 
metabolic processes and include 5-fluorouracil (5-FU) a nucleoside analogue and 
methotrexate a dihyrofolate reductase inhibitor that are clinically approved drugs 25.  
Further, antimicrotubule agents are among the most frequently used drugs for breast 
cancer chemotherapy, with proven efficacy in both localized and metastatic disease. 
It is well known that paclitaxel, one of the taxanes, binds to the microtubules in cells 
and arrests cells in mitosis by stabilizing mitotic spindle microtubules 26.  
 
1.3 Resistance to chemotherapy and targeted therapies 
 
Several mechanisms generating chemoresistance in breast cancer are summarized 
in Figure 3 27. The mechanisms highlighted with a red bordered box are the ones 
examined in this study. 
 
1.3.1 Activated hormone receptors 
 
Many studies have shown involvement of hormones like estrogen receptor (ER) in 
causing chemoresistance 28,29. For instance the ER- breast tumors were found to be 
chemosensitive as compared to the ER+ tumors to six anti-cancer drugs 30. Likewise, 
a lot of mechanisms lead to chemoresistance via ER+ upregulation. Association with 
inactivation of p53, ABC transporter mediated drug resistance, enhanced -tubulin 
expression etc. are few reasons for chemoresistance caused by ER activation 29.  
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(Adapted from: Drug resistance in metastatic castration-resistant prostate cancer, Seruga B, Nat Rev Clin Oncol., 
2011, 8(1), copyright 2010 by Nature Publishing group) 
 
Figure 3. General mechanisms of chemoresistance. Summary of the common mechanisms leading 
to chemoresistance in cells. (a) Activation of hormone receptors (androgen receptor in case of 
prostate cancer as shown here and estrogen receptor in case of breast cancer) leading to activation of 
downstream signaling. (b) Activation of receptor tyrosine kinases which in turn causes activation of 
pro-survival signals. (c) Activation of anti-apoptotic mechanisms usually driven by bcl-2, bcl-xl and 
IAPs. (d) Aberrant angiogenesis causing survival and progression of tumor. (e) Involvement of cancer 
stem cells in resistance. (f) Interactions with microenvironments causing pro-survival signal 
transduction. (g) Increased drug efflux through drug transporters as ABC transporters. The highlighted 
one (red bordered box) are the mechanisms examined for this study 27. 
  
1.3.2 Anti-apoptotic mechanisms 
 
The key players in the apoptosis are Bcl-2 family regulator proteins. Anti-apoptotic 
proteins like Bcl-2 and Bcl-xl play a major role in acquiring chemoresistance. For 
instance, an overexpression of these anti apoptotic factors was demonstrated in 
colon cancer cells resistant to 5-FU 31. Furthermore a study of ovarian cancer cells 
revealed high expression of Bcl-xl in vitro and in vivo after treatment with cisplatin, 
paclitaxel, topotecan, and gemcitabine 32. In contrast treatment of ovarian cancer 
cells with Bcl-2 and Bcl-xl inhibitor ABT-737 in the combination with 
chemotherapeutics displayed more efficacy than the chemotherapeutic treatment 
alone 33. Likewise, there is a preclinical evidence supporting a synergistic therapeutic 
role of the anti-sense therapies of Bcl-xl and Bcl-2 with cytotoxic agents in a wide 
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spectrum of the human cancers, including breast, lung, colon, prostate, gastric, 
epidermis, bladder, hepatoma, cholangiocarcinoma, lymphoma, acute and chronic 
leukemia and melanoma 34,35. Extending this finding to the “inhibitor of apoptosis 
proteins” (IAPs), X-linked inhibitor of apoptosis protein (XIAP) is found to be 
associated with the resistance to 5-FU and gemcitabine in the pancreatic cancer 36. 
Moreover, another IAP Survivin also plays a key role in chemoresistance of 
endothelial cells hence, making it a target for current therapies 37.  
 
1.3.3 Increased drug efflux 
 
Studies and the clinical investigations verify that the initially responsive tumors show 
relapse and resistance to one or multiple drugs used for the treatment. One of the 
mechanisms associated with it is the enhanced drug efflux through the membrane 
transporters. One such transporter family that is extensively studied in terms of the 
drug resistance is the ATP binding cassette (ABC) transporter family. This 
phenomenon of displaying resistance to more than one drug is termed as multiple 
drug resistance (MDR) 38. The ABC family proteins p-glycoprotein, MRP1 and 
ABCG2 are the three major proteins that protect cell from endogenous and 
exogenous molecules and are thus the major contributors to absorption, distribution 
and excretion of the clinically administered drugs 39. A number of ABC transporters 
have been identified that are associated with the breast cancer chemoresistance. 
Table 1 gives an overview of these transporters and their respective drug targets 
hence verifying the vast diversity of these transporter proteins 40. Strikingly, the major 
drugs used in therapy like adriamycin (doxorubicin), paclitaxel, 5FU etc. are the 
targets of the ABC transporter family hence causing resistance to therapies. 
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(Adapted from: Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies, Holen I, International 
journal of breast cancer, 2011, (2011), p 2, copyright 2011 by N. S.Wind and I. Holen) 
 
Table 1. An overview of ABC transporters and their target drugs 40.  
 
1.3.4 Interactions with microenvironment 
 
The effect of micro-environmental factors on chemoresistance can be described in 
two ways. The factors like receptor tyrosine kinases, platelet derived growth factor, 
insulin like growth factor, proteins like TGF, cytokines etc. can interact with and 
modulate each other and in turn act cooperatively on several levels 41-44. Secondly 
there is a crosstalk between the intracellular signaling pathways and pathways of 
adhesion molecules. This crosstalk regulates the intensity and the duration of the 
activation of related pathways leading to complexity. Therefore, it is difficult to 
overcome the survival advantage by blocking only a single target 45. A study 
demonstrated generation of the resistant subclones of mice bearing mammary 
tumors when treated with alkylating agents. After administration of these subclones 
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to other mice, a cross chemoresistance to alkylating agents was observed and this 
effect was restricted to in vivo conditions46. Likewise, the orthotopic human small cell 
lung cancer developed orthotopically in mice were sensitive to cisplatin and resistant 
to mitomycin D. These tumors when injected subcutaneously demonstrated 
resistance to cisplatin and sensitivity to mitomycin D suggesting the role of 
microenvironment in acquiring the resistance 47. Similar results were obtained for 
other types of cancer 48,49. Hence, targeting more than one components of the 
signaling pathways and the interaction cascades is necessary to overcome the 
resistance. 
 
1.3.5 Receptor tyrosine kinases causing resistance to chemotherapy and 
targeted therapies 
 
Receptor tyrosine kinases interact with a number of downstream processing factors 
and hence are involved in activating/suppressing a complex network of pathways 
leading to tumor progression, aggressiveness and chemoresistance. One example of 
the receptor tyrosine kinase is discoidin domain receptor 1 (DDR1). It interacts with 
cyclooxygenase 2 and activates the NFB pathway hence conferring 
chemoresistance 50. Furthermore Src tyrosine kinase activation is associated with the 
5-FU resistance that is reverted by Src inhibitor PP2 51. Apart from this, the activation 
of the epidermal growth factor receptor family especially HER2 is involved 
extensively in chemoresistance 52. For instance, HER2 transfected lung cancer cells 
showed enhanced resistance to chemotherapies  53. Furthermore, the amplification of 
the HER2 gene and overexpression of HER2 protein occurs in 20-25% of breast 
cancers and is often associated with poor prognosis 54-56. Likewise, HER2 
overexpression is also exhibited by the ovarian cancer patients showing resistance to 
chemotherapeutics 57.  
Moreover, the primary adjuvant therapy for the HER2 positive cancers is the 
treatment with trastuzumab that targets HER2. Trastuzumab is a humanized 
monoclonal antibody that binds to the extracellular domain of the HER2 receptor and 
is the first HER2-targeted agent approved for clinical use in breast cancer. Although it 
is one of the most effective treatments in oncology, a significant number of patients 
show resistance to this treatment. Some of the mechanisms of trastuzumab 
INTRODUCTION 
resistance are prevention of trastuzumab binding due to a truncated HER2 receptor, 
the upregulation of HER2 downstream signalling pathways, signalling through 
alternate pathways as PI3K, Akt, IGFR, VEGF etc. and the failure to trigger an 
immune mediated destruction of tumor cells 58-60. A summary of all these 
mechanisms is shown in Figure 4 61.  
 
 
(Adapted from: Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer, Gabriel L, 
International journal of breast cancer, 2011, (2011), p 4, copyright 2011 by G. L. Fiszman and M. A. Jasnis ) 
 
Figure 4. Mechanisms of trastuzumab resistance. This figure summarizes the mechanisms leading 
to trastuzumab resistance. (a) Impaired binding of trastuzumab to the receptor. (b) Increased 
downstream Pro-survival signaling. (c) Increased signaling from dimerization of receptor with other 
receptors of same family. (d) Impaired immune mediated mechanisms 61.  
 
1.3.6  Involvement of cancer stem cells (CSCs) 
 
An emerging concept leading to the chemoresistance is involvement of a less 
differentiated population in escaping the therapies. These cells called cancer stem 
cells or tumor initiating cells or stem cell-like cells have certain properties related to 
stem cells. One of the properties of these cells is “quiescence” or slow proliferation 
that confers resistance to chemotherapeutics 62. Likewise, these cells are present as 
a subpopulation termed as “side population”. It is verified by in cancer cell lines that 
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the side population cells express high amount of ABCG2 and MDR1 transporters 
propelling toxic drugs out of the cells 63-65.  
Stem cell-like population correlated with certain markers like CD44+/CD24- population 
from MCF-7 and SKBR3 cells showed resistance to adriamycin and epirubicin 66. 
Likewise, CD44+/CD24- subset from MCF-7 and MDA MB-231 also showed 
resistance to radiotherapy 67. Overexpression of another cancer stem cell marker 
ALDH1 is associated with resistance to cyclophosphamide in leukemia and colon 
cancer cells 68,69. Hence, there is a need to develop novel therapeutic strategies that 
can target this potential chemoresistant population.  
 
1.4 Heterogeneity: a new dimension to chemoresistance 
 
1.4.1 Cancer stem cells leading to heterogeneity  
 
Human breast cancers are highly heterogeneous group of tumors consisting of 
several morphologically different subtypes 70. A number of factors leading to the 
heterogeneity of breast cancer have been hypothesized and are under study. 
Upcoming mechanism leading to heterogeneity is involvement of cancer stem cells 
causing the same 70-72. Supporting this hypothesis, most of the tumors that arise from 
a single cell eventually end up in constituting cells with different characteristics and 
types.  In fact some cells in a tumor are infiltrating normal cells proposed to support 
the growth of cancer cells 73.  
Moreover, to describe the involvement of cancer stem cells in the tumor progression 
and recurrence, researchers put forward two models.  The model of the “clonal 
evolution” proposes that every cell in a tumor being genetically instable has a 
potential to undergo mutations. Selection of most adaptive phenotype to adverse 
conditions will lead to formation of new tumors and recurrence. This model is 
applicable to many solid tumors like breast, brain, prostrate etc.  
The model of “cancer stem cells” suggests presence of stem cells from the 
commencement of tumors. The stem cells eventually skip therapies due to certain 
properties like “quiescence” and give rise to new tumors. It is also termed as 
“hierarchical model of cancer stem cells” 74. Figure 5 describes the two models for 
involvement of stem cells in formation of new tumors.  
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(Adapted from: The Controversial Clinicobiological Role of Breast Cancer Stem Cells, Casarsa C, Journal of oncology, 
2008, (2001), p 3, copyright 2008 by 2008 Claudia Casarsa et al. ) 
 
Figure 5. Models for heterogeneity in solid cancers. (a) The clonal evolution model puts forward 
the hypothesis that every tumor cell has a potential to undergo mutation and give rise to new tumors. 
The cells adapted to survive adverse conditions (yellow) will dominate and form new tumors. (b) The 
cancer stem cell model depicts that certain population of cells showing stem cell like properties i.e. 
cancer stem cells (pink) exist in the tumor right from the beginning. These cells skip therapy and give 
rise to new tumors 74 
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Residual cancer cells after administration of chemotherapy are termed cancer stem 
cells or tumor initiating cells because of their ability to give rise to the new tumors and 
are therefore responsible for the relapse 62,75. Several markers are explored that 
define this CSC subset 76-80. One of the extensively studied breast cancer stem cell 
subtypes is CD44+/CD24-. The stem cell-like behavior of this subset was verified by 
demonstrating tumor formation after the injection of as few as 200 cells into the 
mammary fat pad of nonobese diabetic/severe combined immunodeficient mice 69,76. 
Apart from this subset, Lin-/CD29high/CD24+ was found in p53 null mice that showed 
potential to initiate the tumor formation 81. Additionally, this population also generated 
entire mammary gland when injected in the mouse mammary fat pad further proving 
its stem cell-like behavior 82. Likewise, ALDH1, MUC1, Sca1 etc. constitute additional 
markers associated with cancer stem cells 55,83,84. Moreover, NANOG, OCT4, and 
SOX2 correlate to the poorly differentiated breast cancers enriched for the cancer 
stem cells 85. Besides, their ability to induce pluripotency and association with the 
chemoresistant cancer stem cell subset from ovarian cancer and osteosarcoma 
nominates them as upcoming markers for determining cancer stem cells 86-89. In 
addition, 3 dimensional spheroids or mammospheres also displayed enrichment for 
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this subset. Furthermore, their 3D architecture resembles tumors better hence 
making them a relevant tool to study cancer stem cells and heterogeneity 78,90,91.  
 
1.4.2 EMT inducing metastasis and heterogeneity 
 
Epithelial cell plasticity can generate distinct cellular subpopulations that contribute to 
the intratumoral heterogeneity in breast cancer. Early studies verified that the breast 
cancer cell lines with the increased invasiveness in vitro and displaying metastatic 
potential in vivo, exhibited expression of the mesenchymal intermediate filament 
protein and marker vimentin 92. This can be explained by the phenomenon termed 
epithelial to mesenchymal transition (EMT). The emergence of EMT is associated 
with the loss of cellular polarity, partial to total destabilization of cell–cell junctions, 
remodeling and replacement of cytoskeletal components, the onset of cell migration 
and the suppression of apoptosis 93. Figure 6 indicate roles of EMT and 
“mesenchymal to epithelial transition“(MET) in tumor progression and metastasis 94.  
Studies suggest that only a small percentage of tumor cells undergo a total transition 
and these cells are presumably the source of the actively metastatic cells 95,96. 
Moreover, recent data verifies association of EMT not only with the invasiveness and 
metastasis but also with the heterogeneity and cancer stem cells 97. Therefore, EMT 
could be utilized as one of the therapeutic targets to minimize heterogeneity, 
metastasis and the progression of tumors.  
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(Adapted from: Epithelial—Mesenchymal andMesenchymal—Epithelial Transitions in Carcinoma Progression, Hugo 
H, Journal of Cellular Physiology, 2007, 213, p 381, copyright 2007 by Wiley-Liss, Inc.. ) 
 
Figure 6. EMT and MET phenomenon in cancer progression and heterogeneity. Tumor 
consisting of epithelial cell mass undergoes the transition from epithelial to mesenchymal cells hence 
giving rise to a heterogeneous tumor (1). Mesenchymal cells then disseminate and migrate (2). Some 
residual cells are left back for the recurrence of epithelial tumor (3, 4). Some migrating cells invade 
blood steam and while maintaining their mesenchymal state gets transported through blood (5, 6). 
This will aid their extravasation and persist there as micrometastases after undergoing MET to form 
epithelial tumors at secondary sites (7, 8) 94.  
 
1.4.3  Interplay of EMT, CSC and RTKs to generate chemoresistance 
 
Cancer stem cells were first discovered in acute myeloid leukemia 98.  Since then, the 
cancer stem cells (CSCs) have been identified in most types of the hematopoietic 
malignancies and recently, CSCs have also been identified in solid tumors, such as 
breast 76,99, brain 100, Colon 101 and prostate cancer 102. Recently, it is shown that 
CD44+/CD24- marker, which is associated with CSCs also describes significantly 
higher relative invasion index than the CD44+/CD24+ cells103.  Likewise, Al-Hajj et al. 
reported that the cells with this phenotype isolated from either primary breast cancers 
or from clinically apparent metastatic lesions have stem cell properties 76. 
Furthermore, data revealed CD44+ cells from both primary tumors and lung 
metastases are highly enriched for tumor initiating cells 104. This complex array of 
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data indicates an association between EMT and CSC that eventually leads to the 
acquisition of chemoresistance. One of the reasons for this association could be 
involvement of pathways like Wnt, notch, hedgehog etc. in EMT as well as in 
maintaining undifferentiated state of stem cells 105.  
Furthermore, receptor tyrosine kinases associated with the chemoresistance are also 
correlated to CSC markers suggesting another crosslink in heterogeneity of breast 
cancer. For instance, HER2, a RTK responsible for tumor progression, metastasis 
and chemoresistance is related with CSC markers as ALDH1 and Notch1 55,106. In 
another study it was found that HER-2 overexpressed in MDA-MB-231 breast cancer 
cells, co-operated with TGF-β to induce an enhanced pro-invasion, angiogenesis, 
and EMT signature correlating HER2 over-expression with EMT 107.   
The interplay amongst phenomenon/ processes taken together induces different 
subpopulations with complex interactions and signalling leading to the 
chemoresistance. Therefore, targeting one of the subpopulation will not eradicate 
entire tumor. Since the current therapies against cancer mainly target the terminally 
differentiated proliferating cancer cells more effectively, investigation of more specific 
treatment regimens is a must for complete eradication of tumor.  
 
1.5 Salinomycin: a potential drug to overcome resistance to classical 
therapies 
 
Salinomycin is a 751 Da transmembrane potassium ionophore obtained from 
bacterium Streptomyces albus. Because of its antibacterial activity it has been used 
widely to control coccidiosis. Being a potassium ionophore, it rapidly embeds in 
biological membranes such as the cytoplasmic and mitochondrial membranes 108,109. 
Gupta et al. demonstrated the eradication of CD44+ cancer stem cells isolated from 
E-cadherin knockdowns of human mammary epithelial cells utilizing salinomycin 
hence proving its potential effect against cancer stem cells for the first time 110. In line 
with this observation, a recent publication showed elimination of side population and 
CD133+ pancreatic cancer stem cells after treatment with salinomycin 111. Likewise, 
salinomycin also inhibited osteosarcoma by selectively targeting the tumor initiating 
cell population positive for OCT4 and SOX2 112. Although its specific effect and 
mechanism of action are yet to be discovered, a latest study showed that it enhances 
apoptosis via increased DNA damage and reduced p21 protein levels through 
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proteasome activity 113. Furthermore, its action is also linked to the ROS generation 
in turn leading to mitochondrial dysfunction and apoptotic cell death 114. A part of this 
thesis intends to target a less differentiated population hence, making salinomycin as 
the drug of choice for the study. 
 
1.6 Aims of the thesis 
 
Functional heterogeneity of the cells within a tumor or selection barriers like 
treatment with chemotherapeutic drugs generate diverse cancer cell populations 
escaping systemic therapy administered routinely in clinics. The residual cells 
survived after the therapy then give rise new tumors. The basic aim of this study was 
to get insight into the process of chemoresistance acquisition for a better 
understanding of the cell types involved in the same. Furthermore, due to their 
architectural resemblance to tumors and the enrichment for cancer stem cell 
subpopulation, utilization of 3D spheroids or mammospheres to study 
chemoresistance had to be evaluated. Additionally, the thesis aimed to determine the 
less differentiated and resistant cancer stem cell population based on the interplay 
between cancer stem cells and membrane receptor tyrosine kinase HER2. 
Recent studies highlighted the potential of an antibiotic salinomycin in specifically 
targeting cancer stem cells/ dedifferentiated cells from tumors 110,112. Hence, its role 
in targeting the identified resistant population was also investigated. Further goal was 
to verify the ability of this drug in combinatorial treatment of heterogeneous breast 
tumor models. All these observations in turn should provide a basis for development 
of novel combinatorial treatment strategies to overcome resistance caused against 
classical therapeutics. 
Moreover, it was shown previously that salinomycin eradicated E-cadherin low 
mesenchymal cells from head and neck squamous carcinomas. Hence, the last part 
of the thesis intended to explore effect of salinomycin on the mesenchymal-like 
breast cancer cell lines. Since the mesenchymal-like cells display aggressiveness 
and metastasis; the effect of salinomycin on migration (basic property of metastatic 
cells) of these cell lines was further investigated.  
 
 
 
MATERIALS AND METHODS 
2. MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Cell lines  
 
MCF-7     Cell line Services, Germany (# 300273) 
MDA MB-231    Cell line Services, Germany (# 300275) 
BT-474 
MDA MB-436 
MDA MB-435    Kindly provided by Prof. A. Ulrich, MPI, 
MDA MB-453    Munich, Germany 
MDA MB-157 
MDA MB- 468 
SKBR-3     Kindly provided by Prof. A. Vollmar, LMU, 
Munich, Germany 
 
2.1.2 Media  
 
DMEM high glucose   Biochrom AG, Berlin, Germany 
L-15 Leibovitz Medium   Biochrom AG, Berlin, Germany 
RPMI 1640     Biochrom AG, Berlin, Germany 
Hams F 12     Biochrom AG, Berlin, Germany 
Mc Coy’s 5A modified medium  Biochrom AG, Berlin, Germany 
 
2.1.3 Chemicals and solutions 
 
Fetal Bovine serum   Gibco/Invitrogen, Karlsruhe, Germany 
(Heat inactivated) (#10500-064) 
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Trypsin EDTA solution Biochrom AG, Berlin, Germany (# L2153) 
Glutamine     Gibco/Invitrogen, Karlsruhe, Germany 
Sodium Pyruvate    Biochrom AG, Berlin, Germany (# L0473) 
polyHydroxyethylmethacrylate  Sigma Aldrich, Steinheim, Germany 
(#P3932) 
Cell dissociation solution  Sigma Aldrich, Steinheim, Germany                          
(# C5789) 
Hoechst 33342  Sigma Aldrich, Steinheim, Germany                   
(# B2261) dissolved in distilled water. 
Verapamil Sigma Aldrich, Steinheim, Germany                   
(# V4269) 
Matrigel  BD Biosciences, Heidelberg, Germany                 
(# 354248) 
Paraformaldehyde Sigma Aldrich, Steinheim, Germany                    
(# 158127) 
Triton X 100 Sigma Aldrich, Steinheim, Germany                   
(# X100) 
Gelatin solution Sigma Aldrich, Steinheim, Germany                   
(# G1393) 
FlourSave mounting reagent Merck KGaA, Darmstadt, Germany               
(# 345789) 
DNAase I (Rnase free) PEQLAB Biotechnologie GMBH, Erlangen, 
Germany (# 10169) 
Cell Stain Millipore S.A.S, France (# 90144) 
Diaminobenzidine Sigma Aldrich, Steinheim, Germany              
(# D8001) 
HEPES sodium salt Sigma Aldrich, Steinheim, Germany              
(# H3784) 
Tissue Tek  Saruka Finetek Europe B.V, Netherlands      
(# 1023000032) 
VSP Super Mega-Cassette® White Saruka Finetek Europe B.V, Netherlands    
 (# VSP-5-9060) 
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2.1.4 Drugs/ Chemotherapuetics 
 
Doxorubicin Sigma Aldrich, Steinheim, Germany                       
(# 44583) 
Paclitaxel Sigma Aldrich, Steinheim, Germany                       
(# T7042) 
Trastuzumab  Kindly provided by Dr. Pjotr  Knyazev, MPI, 
Munich, Germany 
Salinomycin Sigma Aldrich, Steinheim, Germany                       
(# S6201) 
 
2.1.5 Antibodies  
 
SOX2 (H-65) rabbit polyclonal, Santa Cruz Biotechnology, 
USA (# sc 20088) 
OCT4 mouse monoclonal, Santa Cruz 
Biotechnology, USA (# sc 5279) 
E-Cadherin mouse polyclonal, BD Transduction 
Laboratories™, Heidelberg, Germany          
(# 610181) 
 rat monoclonal, Abcam, UK, (# ab11512) 
Vimentin (V9)  mouse monoclonal, Santa Cruz 
Biotechnology, USA (# sc 6260) 
HER2 (c-neu/Ab-2)   mouse monoclonal, Oncogene Research, 
USA (# OP 14) 
Donkey anti mouse Cy3   Thermo Scientific, UK (#PA1-29773) 
Goat anti mouse Al488  Life Technologies GmbH, Germany 
(#A11001)   
Donkey anti rat (Cy TM 3) Jackson ImmunoResearch, UK,                         
(# 712-165-153)  
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Donkey anti rabbit (DyLight tm 488)      Jackson ImmunoResearch, UK,                                        
(# 711-485-152)               
Polyclonal Goat anti rabbit       Dako Denmark A/S (# E0432)   
immunoglobulins / Biotinylated                                                                         
Polyclonal Goat anti mouse       Dako Denmark A/S (# E0433)   
immunoglobulins / Biotinylated                                                                         
 
2.1.6 qPCR Primers (Roche Germany) 
 
GAPDH (UPL Probe #60)   left: ctctgctcctcctgttcgac 
right: gcccaatacgaccaaatcc 
HER2 (UPL Probe #4)    left: gggaaacctggaactcaccta 
right: ccctgcacctcctggata 
NANOG (UPL Probe #69)    left: atgcctcacacggagactgt,  
right: agggctgtcctgaataagca 
OCT4 (UPL Probe #35)    left: agcaaaacccggaggagt 
right: ccacatcggcctgtgtatatc 
SOX2 (UPL Probe #35)    left: ttgctgcctctttaagactagga 
right: ctggggctcaaacttctctc 
 
2.1.7 Mouse models 
 
Crl:SHO-Prkdcscid HRhr double homozygous SCID hairless out bred mice supplied by 
Charles River Laboratories international, inc. USA.  
2.1.8 Kits 
 
Cell titer Glo for cell viability  Promega, Germany, (# G7571) 
Vectastain Elite ABC Kit    Vector labs, UK, (# PK-6200) 
miRCURY RNA Isolation Kit  Exiqon, Denmark (# 300110) 
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Transcriptor High Fidelity cDNA   Roche applied sciences, Germany   
Synthesis Kit                                           (#05081955001) 
     
2.1.9 Special instruments and plasticware 
 
Phase contrast microscope  Carl Zeiss Axiovert 200, Germany 
Fluorescence microscope   Carl Zeiss Axiovert 200, Germany 
 Laser scaning microscope              Carl Zeiss Laser Scanning Microscope LSM       
510 Meta, Germany 
Time Lapse microscope                           Axiovert Carl Zeiss MicroImaging, Germany 
FACS machines                                       FACSCantoTM II, BD Biosciences, Germany                   
                                                                 CyAnTM ADP, Dako cytomations, Germany 
                                                                 FACSAriaTM II, BD Biosciences, Germany                
Real time PCR system                             LightCycler 480 system, Roche, Germany 
Luminometer                                 Lumat LB9507 instrument, Berthold, Bad            
Wildbad, Germany 
FastPrep-24 Tissue/ cell homogenizer       MP Biomedicals Gmbh, Germany (# 6004-
500)  
Hybaid PCR thermal cycler Thermo electro corporation, UK                                       
Well plates (96, 24, 6 well plate)      TPP Techno Plastic Products AG,        
Switzerland 
96 well plates (white for luminescence)  Nunc (Nalgene labware), USA 
48 well plates               Nunc (Nalgene labware), USA 
Plastic dishes (60mm, 100mm)   Nunc (Nalgene labware), USA 
Plastic dishes (150mm)    Sarstedt AG & Co., Germany 
Coverslips                                                Gerhard Menzel GmbH, Germany                            
(# BB024024A1) 
Slides            Gerhard Menzel GmbH, Germany                 
(# AA00008332E)   
40um nylon cell strainer                            BD falcon, NJ, USA (#352340) 
Transwell (cell culture inserts 8 µm)         BD Biosciences, NJ, USA (# 353097) 
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2.1.10 Softwares used 
 
Flowjo 7.6.3 (Flow cytometry analyses). 
Zeiss image browser version 3.2.0.115 (LSM analysis). 
AxioVision image analyses software from Carl Zeiss Microscopy system 
(immunohistochemical analyses). 
AxioVision image analyses software from Carl Zeiss Microscopy system AxioVs40 V 
4.8.1.0 (analyses of phase contrast images). 
Infinity capture Infinity2-3C colour 172765 (capture phase contrast images). 
Capture camera camera MicroMAX, Roper Scientific, Germany using the MetaMorph 
software, Universal Imaging (time lapse microscope). 
Image J software NIH, USA and Chemotaxis and migration tool, Ibidi, Germany 
(analyses of time lapse images). 
 
2.2 Methods 
 
2.2.1 In vitro cell culture assays 
 
2.2.1.1 Maintenance of cell lines 
 All breast cancer cell lines were cultivated as per instructions from purchasing 
company. Briefly, the cell line MCF-7 was cultivated in DMEM high glucose 
supplemented with 20% FBS and 2mM Glutamine. BT-474 was grown in RPMI 1640 
medium supplemented with 10% FBS and 2mM Glutamine. Both these cell lines 
were incubated at 370 C and 5% CO2 humidified atmosphere. Cell lines MDA MB-
231, MDA MB-453, MDA MB-436, MDA MB-157 and MDA MB-468 were cultivated in 
L-15 Lebovitz medium supplemented with 10% FBS and 2mM Glutamine and were 
incubated at 37oC without CO2 humidified atmosphere. SKBR-3 was cultivated in Mc 
Coy’s 5A modified medium supplemented with 10% FBS and 2mM Glutamine. MDA 
MB-435 cells were grown in were cultivated in DMEM/Ham’s F-12 medium 1:1 
supplemented with 10% FCS and 2mM stable glutamine. These cell lines were 
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incubated at 37oC and 5% CO2 humidified atmosphere. 1X trypsin EDTA solution 
was used for splitting of all the cell lines.  
2.2.1.2 Freezing and thawing of cells 
By addition of an anti-freezing compound like DMSO, eukaryotic cell lines can be 
stored in liquid nitrogen for several years. To store cells in liquid nitrogen, cells were 
spun down at 1000rpm for 5 min at room temperature. Then freezing medium 
containing 90% medium and 10% DMSO was added to cell pellet. Cells were then 
kept first at -80oC at least for 24 hrs before transferring it into liquid nitrogen. 
For reculturing of the frozen cells, the cell suspension was defrosted at 37°C and 10 
ml of medium was added to dilute out DMSO. After centrifuging at 1000 rpm for 5 min 
at room temperature, fresh medium was added to cell pellet and incubated.  
 
2.2.1.3 Mammospheres generation and cultivation 
Mammospheres were generated as described previous 91. Briefly, dishes were 
coated with 50 µg/ml PolyHEMA. Medium from the 2D cells grown to a confluency of 
80-85% was taken as conditioned medium for growing mammospheres. Single cells 
were seeded in conditioned medium into polyHEMA coated dishes at the 
concentration of 40,000 cells/ml. Splitting and passaging of mammospheres was 
performed as stated earlier 115. Mammospheres were harvested, incubated with non 
enzymatic cell dissociation solution at 37°C. Cells were dispersed by pipetting gently 
and passing through 40um nylon cell strainer once to obtain single cell suspension. 
After centrifugation at 900 rpm for 5 min at room temperature cells were resuspended 
in conditioned medium and seeded. 
 
2.2.1.4 Cell viability assay 
To check the effect of different drugs on different cell lines this assay was performed. 
5000 cells per well of a 96 well plate were seeded. Mammospheres were divided in 
two parts. One half was trypsinized and cells were counted to a final concentration of 
5000 cells per well. Accordingly, whole mammospheres were seeded in a 50 µg/ml 
Polyhema coated 96 well plate (Figure 14 a). Treatment was performed after 24 hrs 
of seeding. Treatment were performed as follows 
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Treatment Cells Time 
Doxorubicin/ Paclitaxel 2D cells and 
mammospheres 
72 hrs 
Trastuzumab/ Salinomycin Sorted populations 7 days 
Combinatorial (Trastuzumab 
and Salinomycin) 
mammospheres 7 days (first with 
trastuzumab and after 
96 hrs salinomycin was 
added) 
Doxorubicin/ Salinomycin Epithelial/ mesenchymal 2D 
cells 
72 hrs 
Combinatorial (Doxorubicin 
and Salinomycin) 
Mixture of epithelial and 
mesenchymal 2D cells 
72 hrs 
 
Cell titer Glo assay was performed for cell viability according to the manufacturer’s 
instructons. This assay utilizes the detection of ATP content of cells thereby directly 
indicating the no. of live cells in sample. The luminescence was recorded with a 
Luminometer. 
To check effect of the drugs on mammospheres, mammospheres were divided in two 
halves. One half was trypsinized into single cells followed by counting the amount 
required to seed 5000 cells/well and accordingly whole mammospheres were seeded 
in poly HEMA coated 96. Treatment was performed after 24 hrs (Figure 15 a). Cell 
viability was determined after the treatments. 
 
2.2.1.5 Mammosphere forming potential assay (MFP) 
To identify the property of cells to sustain the formation of mammospheres over the 
passages, this assay was performed. 5000 single dissociated cells of 2D cell line 
were seeded in polyHEMA coated 60 mm dishes. After 7 days i.e. at passage 0, no. 
of mammospheres generated was counted. Mammospheres were dissociated into 
single cells using non enzymatic cell dissociation solution and cell strainer and above 
procedure was repeated until passage 2 (P2) 116. Graph was plotted after 
calculations were performed for P0, P1 and P2.  
MATERIALS AND METHODS 
 31
 
2.2.1.6 Molecular evolution assay (MEA) 
This assay was developed to characterize the resistance of cells to the 
chemotherapeutics. BT-474 and MDA MB-468 cell lines were treated with 0.5µM 
doxorubicin (DXR) in cycles. This concentration of doxorubicin was selected as it 
eradicated almost 50% of the cells. The treatment was performed for 72 hrs followed 
by change in media and recovery phase for the cells. After each round of recovery, 
cells were analyzed for their response to doxorubicin and were subjected to 
functional assay like the quantification of mRNA level of certain genes, the ability of 
cells to form mammospheres and the percentage of side population (Figure 7). 
  
2.2.1.7 Proliferation assay 
5000 sorted cells of HER2high and HER2low fractions of MCF-7 2D and MCF-7 
mammospheres (7 days old) were seeded and counted using counting chamber 
(Fuchs-Rosenthal counting chamber) at day 2, 4, 6 and 8. 
 
2.2.1.8 3D Matrigel Assay 
3D Matrigel assay was performed as described previously 117. Briefly, 8 well chamber 
slides were coated with 100µl of pure Matrigel and were allowed to polymerize at 370 
C for 15-20 min. 5000 cells were added in a small volume of medium and allowed to 
adhere to the coating for 2-5 min. Then 75µl medium with 20% Matrigel was added 
on top of it. 50µl of medium was supplemented once a week and the no. of colonies 
formed were counted after 7 days. Phase contrast microscopic images with 10X 
objective were taken using Infinity capture (Infinity2-3C colour 172765) software and 
were analysed using Axiovision Rel 3.1 software. 
 
2.2.1.9 Wound healing assay for cell migration 
MDA MB-436 cells were seeded in a 6 well plate. When 96-98% confluency was 
reached, a small scratch was made using melted pasture pipette tip (bulb shaped). 
Floating and dead cells were washed out using media without FCS and respective 
media was added to wells. One well was kept untreated as control followed by 
addition of 0.05M doxorubicin to second well and 0.05M salinomycin to the third 
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well. Migration of cells in the wound was assayed with a live-cell imaging setup 
consisting of a microscope equipped with a 10X 0.3NA objective, motorized scanning 
table and a stage incubator (EMBL Precision Engineering) at 37°C and under 5% 
CO2 atmosphere. Images were captured with a cooled charge-coupled-device 
camera (MicroMAX; Roper Scientific, Germany) using the MetaMorph software 
(Universal Imaging) for microscope control and data acquisition. Images were taken 
after every 15 min for 72 hrs and the data was analyzed using Imaje J software (NIH, 
USA) and Chemotaxis and migration tool (Ibidi, Germany). This assay was 
performed utilizing concentrations of drugs at which only 15-20% apoptosis or cell 
death was observed after 72 hrs treatment as determined by Cell titer Glo assay. 
 
2.2.1.10 Transwell migration assay 
This assay for confirmation of cell migration was performed as described earlier 118. 
Briefly, Cell culture inserts i.e. transwells (8 µm pore size), were placed in wells of 24 
well plate containing 10% FBS in medium plus or minus 10M doxorubicin or 0.05M 
salinomycin. Cells suspended in 0.2 ml serum free medium (plus or minus drugs) 
were added to the top of each chamber followed by incubation at 37oC with 1% CO2 
for MDA MB-436 cells. After 18 hrs the chambers were washed with dH2O and the 
cells removed from the topside of the chamber with a cotton swab. Migrating cells 
were fixed and stained using the cell stain solution. The average number of migrating 
cells from fifteen representative fields (10X objective of phase contrast microscope, 
three wells per condition) was obtained. Graph was plotted according to the readings 
obtained. This assay was performed utilizing concentrations of drugs at which only 
10-15% apoptosis or cell death was observed after 18 hrs treatment as determined 
by Cell titer Glo assay. 
 
2.2.1.11 Generation of in vitro mimic of metastatic breast tumor  
MCF-7 single cells and MDA MB-436 single cells were mixed in a ratio 1:1 and 
seeded in dishes in mixture of DMEM medium with 20% FCS and L-15 Lebovitz 
medium with 10 % FCS in ratio 1:1. Cells were incubated at 37oC and 5% CO2 
humidified atmosphere. Images were captured using phase contrast microscope.  
For cell viability assays, MCF-7 and MDA MB-436 cells were mixed in 1:1 ratio and 
5000 cells were seeded/ well of 96 well plate. Cells were treated either with DMSO 
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(as control), doxorubicin and salinomycin either individually or in combination. Cell 
titer Glo assay was performed after 72 hrs of treatment.  
 
2.2.2 Histological and Immunofluorescence methods 
 
2.2.2.1 Side population analysis 
Side population analysis of BT-474 cells and MDA MB-468 cells was performed as 
suggested in Goodell et. al 119. Single cells were resuspended at 106 cells/ ml in 
prewarmed DMEM solution (Appendix2). One set was kept unstained as control. To 
one set Hoechst 33342 was added at the concentration of 1 µg/ 106 and to another 
set both Hoechst 33342 and verapamil (50 µM/ sample) were added. Samples were 
incubated incubated for 90 min at 370 C in waterbath. After Hoechst staining, cells 
were pelleted and maintained at 40 C before analyzing with Flow cytometry (CyAnTM 
ADP Flow cytometer). Percent side population (% SP) was counted by subtracting 
the % SP in only Hoechst stained samples with % SP of samples stained with both 
Hoechst and verapamil.  
 
2.2.2.2 Flow cytometry and Fluorescence-activated cell sorting 
Single cell suspension of 2D cell lines and 3D mammospheres was prepared using 
non enzymatic cell dissociation solution. For indirect immunofluorescence cells were 
fixed with 4% paraformaldehyde (PFA) for 15 min at room temperature, 
permeabilized with permeabilization solution (Appendix 2) for 10 min and blocked 
with blocking solution (Appendix 2) for 45 min at room temperature. Cells were 
incubated with indicated primary antibodies (1:100) and labeled with appropriate 
fluorescence coupled secondary antibodies (1:200). Fluorescence was acquired 
using FACSCantoTM II flow cytometer.  
For cell sorting, single cell suspension was prepared under aseptic conditions. Cells 
were blocked using FBS for 30-40 min on ice. Incubations with primary (1:100) and 
secondary antibodies (1:200) were performed for 1 hr each on ice. Just before 
sorting of cells 20U/ml DNAaseI enzyme was added to avoid clumping of cells due to 
remains of genomic DNA and 1µg/ml propidium iodide was added to exclude out the 
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dead cells. Cell sorting was performed using indicated antibodies with a FACSAriaTM 
II cell sorter. 
 
2.2.2.3 Immunocytology and microscopy 
100, 000 cells of 2D cell lines were seeded on coverslips in 6 well plates. After they 
reached confluency of 70-80% cells were fixed with 4% PFA for 15 min. Whole 
mammospheres were centrifuged at 1000 rpm for 5 min for collection and fixed with 
4% PFA for 20 min. Samples were then permeabilized with permeabilization solution 
(Appendix 2) for 10 min (2D cells) and 15 min (mammospheres) followed by blocking 
with blocking solution (Appendix 2) for 45 min. Incubation with indicated primary 
antibodies (1:100) was performed for 1 hr followed by incubation with respective 
secondary antibodies (1:200) for 1 hr. Nucleus was stained with  DAPI for 10-15 min. 
All incubations were performed at room temperature and for mammospheres cell 
pelletting was performed at 1000 rpm for 5 min. For 2D cells coverslips were 
mounted using FlourSave mounting medium and were stored at 4oC. Images were 
captured using 63 X 1.4 Oil DIC objective of Laser Scanning Microscope LSM 510 
Meta and analyzed using Zeiss image browser version 3.2.0.115.  
 
2.2.2.4 Immunocytochemistry of tissue sections  
5-7µM tissue sections were prepared from xenografts of MCF-7 2D and MCF-7 
mammospheres injected subcutaneously in female immunodeficient mice after 170 
days. The tissue tek layer was removed and the sections were fixed with 4% 
paraformaldehyde for 10-15 min. After blocking with 5% FBS in PBS twice for 10 min, 
HER2 antibody (1:200) was added for 2 hrs. Secondary antibody (1:400) and DAPI 
(1:1000) were added for an hour and sections were treated with FluorSave reagent. 
Results were captured using 63 X 1.4 Oil DIC objective of Carl Zeiss Laser Scanning 
Microscope LSM 510 Meta and analysed using Zeiss image browser version 
3.2.0.115.  
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2.2.2.5 Immunohistochemistry of tissue sections 
Immunohistochemical analysis was performed as described 120. Slides (5-7µM 
sections) were incubated for 15 minutes with 0.3 % H2O2 in methanol (for Oct 4) and 
1.5 % H2O2 in PBS (for HER 2) to quench endogenous peroxidase. An antigen 
retrieval step was performed using 10mM Sodium citrate buffer, pH 6.0 and cooking 
the tissue in the microwave for few (15 minutes for HER 2 and 10 minutes for OCT 
4). After cooling down at room temperature for at least 30 to 45 minutes, the sections 
were washed with tap water and three times for five minutes each with PBS. Before 
incubation with the primary antibody, the sections were blocked for few hours (from 
30 minutes to 2 hours) at room temperature with the appropriate serums, Triton X-
100 in PBS. The primary antibody is diluted in the blocking solution in appropriate 
concentrations (1:100) and was incubated at 4°C overnight. Next day the sections 
were washed three times for five minutes each with PBS. The secondary antibody 
(biotinylated) was diluted 1:200 in blocking solution and the sections were incubated 
for few hours (1 to 2 hours). Before applying the A+B reagent (Vectastain Elite ABC 
Kit) that was prepared 30 minutes before 1:1 for 40 minutes at room temperature, the 
sections were washed again three times for five minutes each with PBS. Afterwards, 
the sections were washed again three times for five minutes each with PBS and 
incubated with DAB (1ml DAB + 0.8ul of 30% H2O2, Hydrogen peroxide) until the 
appearance of brown colour. The reaction was stopped with tap water for 5 minutes 
and afterwards the tissue was counterstained shortly with hematoxylin , washed with 
tap water, dehydrated and mounted with Entellan. Control sections were processed 
without primary antibody. Images were captured via the Version 4.7 of the AxioVision 
image analysis software from Carl Zeiss Microscopy system. 
 
2.2.3 Molecular biology methods 
 
2.2.3.1 mRNA Isolation 
mRNA isolation was performed by miRCURYTM RNA isolation kit (Exiqon). To 
describe the procedure for cell lines, cells were washed with 1X PBS and cells lysis 
soluntion (350µl-1000µl depending on size of dish) was added. At this stage the 
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lysates can be stored at -70oC for few hrs or days. After addition of 200µl of 95-100% 
ethanol lysates were vortexed for 10 sec and the whole mixture was transferred to 
the column. After centrifugation for 1 min at 14,000g, wash 400µl of solution was 
applied to the column and was again centrifuged. For elution of the total RNA, 50µl of 
elution buffer was applied to the column and it was centrifuged for 2 min at 14,000g. 
At this step purified RNA samples could be stored at -20oC for a few days or -70oC 
for longer period. 
For preparing RNA from tissue sample, tumors were homogenized in FastPrep-24 
Tissue and cell homogenizer while in lysis buffer and the lysates were subjected to 
similar RNA isolation procedure.  
 
2.2.3.2 cDNA preparation 
cDNA was isolated from the RNA by using Transcription High Fidelity cDNA 
Synthesis Kit (Roche). Random hexamer primer and PCR grade water was added. 
The sample was heated in thermo cycler (with a heated lid) at 65oC for 10 min to 
denature the template followed by chilling on ice. To this mixture, remaining contents 
of RT mix (buffer, protector, dNTPs, DTT, Reverse Transcriptase) were added to the 
final volume of 20µl and the mixture was kept in thermocycler with heated lid at 29oC 
for 10 min. and then at 48oC for 60 min. The reverse transcriptase was inactivated by 
heating to 85oC for 5 min and reaction was halted by placing the tube on ice. The 
cDNA prepared was then stored at -20oC for longer perdios before using it for qPCR 
reaction.  
 
2.2.3.3 qPCR analysis 
Quantitative real-time PCR was performed using UPL Probes (Roche) and Probes 
Master (Roche) on a LightCycler 480 system with GAPDH as control. Primers used 
include GAPDH, HER2, NANOG, OCT4, SOX2. Experiments were performed in 
triplicates and the obtained average CT values of target genes were normalised to 
control as ΔCT. Changes in expression levels were shown either as fold increase or 
as ratio (target gene/ control). 
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2.2.4 In vivo xenograft experiments 
1 x 105 immunosorted MCF-7 HER2low and HER2high cells were injected 
subcutaneously into the right flank of 5 – 7 weeks old female Crl:SHO-Prkdcscid HRhr 
double homozygous SCID hairless out bred mice (7 mice per group). Before 
inoculation cells were resuspended in PBS and Matrigel (1:1). Tumor volume was 
measured once or twice a week using a calliper beginning at day 9 of injection. The 
volumes were calculated by the formula 0.5 x d2 x D (where d represents the smaller 
and D represents the larger diameter). For growth curve data points were expressed 
as average tumor volume [mm3] +/- SD per group (HER2low and HER2high). After 145 
days, mice were sacrificed and tumors were resected for cryosections and qPCR.  
For xenografts of MCF-7 2D cell line and MCF-7 mammospheres, 1 x 106 single cells 
were injected subcutaneously into the right flank of female Crl:SHO-Prkdcscid HRhr 
double homozygous SCID hairless out bred mice (5 mice per group). Mice were 
sacrificed after 170 days and cryosections were prepared from the resected tumors 
in tissue tek medium using mega cassette. All animal procedures were approved and 
controlled by the local ethics committee and carried out according to the guidelines of 
the German law of protection of animal life. 
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3. RESULTS 
 
3.1 Evolution of chemoresistance to classical chemotherapeutics in vitro 
 
Most of the chemotherapeutics used in the clinics these days affect fast proliferating 
cells. Since, at the time of treatment not all tumor cells are in the same phase of cell 
cycle, chemotherapy is administered in cycles. A cycle of chemotherapy (which is 
typically 21 or 28 days) refers to the time it takes to give the treatment and then allow 
the body to recover from the side effects of the medicines. The period of recovery 
can give rise to resistant cells that are able to skip therapy and hence cause 
recurrence of tumor. To mimic this clinical system and to characterize the evolution of 
resistance to chemotherapeutics, we designed an assay named ‘Molecular evolution 
assay’ (MEA). A schematic representation of MEA is shown in figure 7. Briefly, two 
representative epithelial breast cancer cell lines BT-474 and MDA MB-468 were 
treated with 0.5µM doxorubicin (DXR) in cycles. This concentration of doxorubicin 
had been selected as it eradicated almost 50% of the cells. The treatment was 
performed for 72 h followed by change in media and recovery phase for the cells. 
After each round of recovery, cells were analyzed for their response to doxorubicin 
and were subjected to functional assay like the quantification of mRNA level of 
certain genes, the ability of cells to form mammospheres and the percentage of side 
population. 
Recovered cells from each round of MEA were analyzed for their acquired resistance 
to doxorubicin. Comparison of cell viability assay displays evolution of resistant cells 
in round 3 (R3) and round 4 (R4) for both BT-474 and MDA MB-468 (Figure 8 a and 
b). 
Additionally, the IC50 values indicate R3 and R4 cells acquired resistance against 
doxorubicin as compared to R1 cells for both cell lines (Table 2). 
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Figure 7. Schematic representation of the Molecular Evolution Assay (MEA). BT-474 and MDA 
MB-468 cells were treated with 0.5 µM doxorubicin for 72 h followed by a recovery phase. Recovered 
cells were subjected to qPCR analysis and functional assay like cell viability assay, side population 
analysis and mammospheres forming potential analysis. Four treatment rounds were performed for 
each cell line (R1-R4). 
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
BT-474 MEA 
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b) MDA MB-468 MEA 
 
Figure 8. Cell viability assays of recovered cells from each MEA round against doxorubicin. 
Recovered cells from each round of MEA (Figure 7) were treated with doxorubicin for 72 h and Cell 
titer Glo assay was performed. Each treatment was done in triplicates. (a) Cell titer Glo assay results 
for BT-474 cells recovered from each round of MEA (R1-R4). (b) Cell titer Glo assay results for MDA 
MB-468 cells recovered from each round of MEA (R1-R4). Representative graphs of one 
concentration are shown here.  
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Table 2. IC50 values of doxorubicin for BT-74 and MDA MB-68 cells of R1-R4.  
 
The percentage of side population (SP) of the cells indicates the amount of ABC 
transporters present in the cells, which in turn help in pumping out the drugs and 
skipping the therapy. Percentage SP analysis of BT-474 and MDA MB-436 showed a 
gradual increase in ABC transporters over the rounds for both cell lines indicating 
evolution of resistant cells after cycles of treatment with doxorubicin (Figure 9 a and 
b). 
 
 
     
a) b) 
 
Figure 9. Percentage side population of BT-474 and MDA MB-468 cells obtained from rounds of 
MEA (Figure 7). (a) Percentage side population of BT-474 cells obtained from round 1 (R1), round 2 
(R2) and round 3 (R3). (b) Percentage side population of MDA MB-468 cells obtained from round 1 
(R1) and round 2 (R2). 
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After confirming the increased drug resistance over the rounds of the MEA by 
performing different assays, we wanted to check the effect of the treatments on the 
formation of mammospheres (detailed explanation in chapter 3.2) of both cell lines. 
Therefore we performed a ‘mammosphere forming potential’ (MFP) assay up to 3  
RESULTS 
 
passages of cells after each round of the treatment. For the cell line BT-474, 
treatment round 1 showed a constant MFP with around 200 mammospheres formed 
per passage. But in treatment round 2, cells showed decreased no. of 
mammospheres over passages and cells from treatment round 3 and 4 could not 
generate any mammospheres (Figure 10 a and b). Similar pattern was observed for 
MDA MB-436 cells where no. of mammospheres decreased over passages and over 
rounds. No mammospheres were formed for cell from round 3 and 4 (Figure 10 c and 
d).  
 
 
  
a) b) BT- 474 R2 MFP BT- 474 R1 MFP 
 
 
  
c) MDA MB-468 R1 MFP d) MDA MB- 468 R2 MFP 
 
Figure 10. Mammosphere forming potential (MFP) of BT-474 and MDA MB-468 cells obtained 
from rounds of MEA. (a) MFP of round 1 (R1) cells of BT-474. (b) MFP of round 2 (R2) cells of BT-
474. R3 and R4 cells showed no mammospheres formation. (a) MFP of round 1 (R1) cells of MDA 
MB-468. (b) MFP of round 2 (R2) cells of MDA MB-468. R3 and R4 cells showed no mammospheres 
formation. All experiments were performed in triplicates (n=3).  
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3.2 Generation and utilization of mammospheres as tools to study 
chemoresistance 
 
Three dimensional spheroids of the breast cancer cells or mammary cells are known 
as mammospheres (MS). 3D architecture confers certain properties that distinguish 
mammospheres from 2D cell lines. Additionally, these spheroids resemble the 
tumors better because of their cellular heterogeneity. Furthermore, mammospheres 
are also enriched in certain markers conferring a chemoresistance phenotype on 
them. Considering all these properties, mammospheres were taken as tools to study 
chemoresistance in this thesis.  
As shown in Figure 11, different breast cancer cell lines gave rise to different types of 
mammospheres. Based on the morphologies, mammospheres were divided into 
categories (Table 3).  Epithelial cell lines like MCF-7 and BT-474 showed tight 
spheroids with merged cellular boundaries and defined spheroid shape. On the other 
hand, aggressive cell lines like MDA MB-436 and MDA MB-231 showed formation of 
aggregates. The aggregates were further divided in two categories loose aggregates 
as shown by MDA MB-231, MDA MB-157 and MDA MB-468 as well as tight 
aggregates shown by MDA MB-435, MDA MB-436 and MDA MB 453. The 
mammospheres structures of cell lines like MDA MB-231 and MDA MB-436 owing 
compromised cell–cell adhesion, acquisition of EMT like characters, and increased 
invasiveness demonstrated invasive and protrusive structures. In support to these 
results, a study showed appearance of MDA MB-231 mammospheres as aggregates 
due to invasive nature of the cell line. These aggregates eventually formed tight 
spheroids after addition of reconstituted basement membrane 121. Furthermore, Shaw 
et. al, 2004 also discuss loss of polarity of mammospheres after reduction in E-
cadherin levels 122.  
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MCF-7 2D MCF-7 MS 
 
  
BT-474 2D BT-474 MS 
 
  
MDA MB-435 2D MDA MB-435 MS 
 
 
 
 44
RESULTS 
 
 
MDA MB-436 2D 
  
MDA MB-436 MS 
 
 
  
MDA MB-453 MS MDA MB-453 2D 
 
 
MDA MB-231 2D 
  
MDA MB-231 MS 
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MDA MB-157 2D 
  
MDA MB-157 MS 
 
  
MDA MB-468 MS MDA MB-468 2D 
 
Figure 11. Morphology of different breast cancer cell lines and their mammospheres. Different 
morphologies of mammospheres were obtained based on different cell types and properties. MCF-7 
and BT-474 displayed tight spheroids. MDA MB-435, MDA MB-436 and MDA MB-453 showed tight 
aggregates. MDA MB-231, MDA MB-157 and MDA MB-468 demonstrated loose aggregates. For 2D 
cells the images were captured at 48 h and for mammospheres the images were captured after 7 d of 
seeding. 
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Table 3. Classification of mammospheres of different breast cancer cell lines. 
 
To check the ability the cell lines to form and propagate heterogeneous 
mammospheres, mammosphere forming potential (MFP) assay was performed. 
Moreover in this assay mammospheres were generated utilizing as low as 5000 
single cells (passage 0). Cell from mammospheres were dissociated into single cells 
and seeded again to form mammospheres of passage 1 (P1). The assay was 
performed till passage 2 (P2). Cell lines with high E-cadherin expression (MCF-7 and 
BT-474) showed more or less constant MFP (Figure 12 a). On the contrary invasive 
cell lines like MDA MB-231, MDA MB-436, MDA MB-468 and MDA MB-157 showed 
decreased MFP (Figure 12 b). Furthermore, MDA MB-453 showed presence of far 
less mammospheres and hence seeding for passage 1 was not possible. MDA MB-
435 was the only exception that showed increased MFP (Figure 12 c). 
 a) Constant MFP 
 
   
BT-474 MCF-7 
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 b) Decreasing MFP 
 
   
MDA MB-231 MDA MB-436 
 
 
MDA MB-157 
   
MDA MB-468 
 
 
 
MDA MB-453 
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 c) Increasing MFP 
 
MDA MB-435 
 
 
Figure 12.  Mammosphere forming potential (MFP) of breast cancer cell line mammospheres 
upon passaging. (a) Constant MFP of MCF-7 and BT-474 from passage 0 (P0) to passage 2 (P2). 
(b) Decreasing MFP of MDA MB-231, MDA MB-436, MDA MB-468, MDA MB-157 and MDA MB-453. 
(c) Increasing MFP of MDA MB-435. For each passage mammospheres were counted after 7d of 
seeding. Student’s t test is performed to determine the significance (*** P-values <0.001, ** P-values 
<0.01, * P-values <0.05) 
 
Furthermore, to correlate breast cancer chemoresistance, investigation of stem cell-
like character in mammospheres was performed. NANOG, OCT4 and SOX2 (NOS) 
genes were selected as stem cell markers. Figure 13 a shows qPCR analysis of 
expression of the three genes in mammospheres. Mammospheres of all three cell 
lines namely MCF-7, MDA MB-435 and MDA MB-231 show up-regulation of NOS 
genes as compared to 2D cells. Amongst the mammospheres of three cell lines, 
MCF-7 mammospheres demonstrated highest levels of these genes NANOG (4.5 
fold), OCT4 (1.5 fold) and SOX2 (8 fold) as compared to 2D MCF-7 cell line. To 
confirm qPCR data, FACS staining for SOX2 marker was performed. An over-
expression of SOX2 gene was depicted in MCF-7 and MDA MB-453 mammospheres 
by FACS analysis (Figure 13 b).  
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a) MCF7 2D vs MS 
 
 
MDA MB-453 2D vs MS 
 
 
MDA MB-231 2D vs MS 
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b) 
Figure 13. Enrichment of stem cell markers in mammospheres (MS) as compared to 2D cells. 
(a) qPCR analysis of markers NANOG, OCT4 and SOX2 in mammospheres of MCF-7, MDA MB-453 
and MDA MB-231 as compared to 2D cells. The results here are displayed as fold increase of markers 
in mammospheres as compared to 2D cells. (b) FACS analysis of marker SOX2 in mammospheres as 
well as 2D cells of MCF-7 and MDA MB-453. Total SOX2 levels are shown in the overlay. 
 
After demonstrating enrichment of stem cell-like cells in mammospheres, their 
sensitivity to chemotherapeutics was analyzed. MCF-7 mammospheres and 2D cells 
were subjected to treatment with different classical chemotherapeutics. Briefly, MCF-
7 mammospheres were divided in two halves. One half was trypsinized into single 
cells followed by counting the amount required to seed 5000 cells/well and 
accordingly whole mammospheres were seeded in poly HEMA coated 96. Treatment 
was performed after 24 hrs of seeding for 72 hrs (Figure 14 a). Mammospheres 
showed significant resistance to doxorubicin and paclitaxel as compared to 2D MCF-
7 cells (Figure 14 b and c). In toto, these results indicate potential of mammospheres 
as tools to study chemoresistance due to their morphological phenotype, 
resemblance to tumors and enrichment for stem cell-like cells.   
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b) 
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c) 
 
Figure 14. Utilization of mammospheres as tools to study chemoresistance.  (a) Scheme for 
studying effect of chemotherapeutics on mammospheres. Treatment was performed as stated in the 
text for both 2D cells as well as mammospheres and cell viability was checked through Cell titer Glo 
assay. (b) Effect of doxorubicin on MCF-7 2D cells and 7 d old MS. (c) Effect of paclitaxel on MCF-7 
2D cells and 7 d old. Each treatment was performed in triplicates (n=3). 
 
3.3 Elevation of membrane receptor tyrosine kinase HER2 in 
mammospheres 
 
Pickl and Ries demonstrated a difference in molecular signaling of HER2 in 
mammospheres and 2D cell lines 123. HER2 is an extensively studied growth and 
survival marker in breast cancer and is associated with the chemoresistance making 
it one of the intriguing proteins for this study. An analysis of HER2 expression in 
mammospheres was further performed in this study. Strikingly, MCF-7 and MDA MB-
453 mammospheres corroborated increased expression of HER2 at mRNA as well 
as protein levels as compared to respective 2D cell lines (Figure 15 a and b). 
Additionally, tissue sections from xenografts obtained by injecting single cells from 
mammospheres in mice exhibited expression of HER2 which was absent in tissue 
sections of injected MCF-7 2D cells (Figure 15 c). 
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a) 
 
         
b) 
 
            
MCF-7 2D 
HER2 
MCF-7 MS  
DAPI c) DAPI 
 
Figure 15. Up regulation of HER2 protein in MCF-7 MS. (a) qPCR analysis of HER2 levels in MCF-
7 and MDA MB-453 mammospheres as compared to 2D cell lines. The experiment is performed in 
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triplicates (n=3). Student’s t test is performed to determine the significance (*** P-values <0.001, ** P-
values <0.01). (b) FACS analysis of protein HER2 in mammospheres as well as 2D cells of MCF-7 
and MDA MB-453. Total HER2 levels are shown in the overlay. (c) Cells of MCF-7 2D and MCF-7 
mammospheres were injected subcutaneously in the right flank of female immunodeficient mice and 
cryosections were prepared after 171 d of injection. Tissue sections were stained for HER2 protein 
(red) and the nucleus is stained with DAPI (blue). A section of 20 µm is shown here. 
 
Laser scanning microscopic images of MCF-7 and MDA MB-453 mammospheres 
stained for HER2 displayed differential membrane expression in individual cells of 
mammospheres (Figure 16 a and b). Some cells showed strong membrane localized 
HER2 expression (white arrows) whereas some showed no or little HER2 expression 
(red arrows). To characterize these populations and identify the role of HER2 in 
mammospheres, two cell fractions were immunosorted.  
 
 
        
b) MDA MB-453 MS a) MCF-7 MS 
HER2 
DAPI 
 
Figure 16. Differential expression of HER2 protein in mammospheres. (a) Laser scanning 
microscopic images of MCF-7 mammospheres stained for HER2 (red). Nucleus is stained with DAPI 
(blue).  White arrows show membrane staining of HER2 and red arrows indicate HER2low cells. (b) 
Laser scanning microscopic images of MDA MB-453 mammospheres stained for HER2 (green). 
Nucleus is stained with DAPI (blue).  White arrows show membrane staining of HER2 and red arrows 
indicate HER2low cells. A section of 10µm is shown here. 
 
10% of the cell population containing highest HER2 levels as HER2high and 10% of 
cells with the lowest HER2 expression as HER2low were sorted from MCF-7 
mammospheres. Accordingly, analysis of the location of these two fractions in 
forward scatter and sideward scatter plot of the whole population showed HER2low as 
a small cell fraction (Figure 17).  
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Figure 17. Strategy to immunosort HER2low and HER2high cells from MCF-7 MS.   
10 % of HER2high and 10 % of HER2low cells were sorted from 2D cell line and mammospheres of 
MCF-7 grown for 24 h and 7 d. HER2low is distinctly present in the small cell fraction and HER2high is 
primarily present in the big cell fraction as analyzed in forward scatter and sideward scatter plot. 
 
To determine the role of HER2 protein expression in formation of mammospheres, 
these two immunosorted populations from 7 d old mammospheres of MCF-7 were 
subjected to the MFP analysis. In accordance with the study of Hanssen et al. 2010, 
HER2high fraction showed significantly high number of mammospheres formed even 
at passage 2 (P2) as compared to those formed by HER2low fraction 124. In addition 
HER2low fraction showed gradual decrease in the number of mammospheres formed 
starting from passage 0 (P0) to passage 2 (P2) (Figure 18 a and b). This data 
suggests involvement of HER2 in anoikis resistance and formation of 
mammospheres.  
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Figure 18. MFP of HER2high and HER2low sorted populations from MCF-7 MS. MFP of HER2high 
and HER2low sorted cells from MCF-7 mammospheres from P0 to P2. Experiments were performed in 
triplicates (n=3). Student’s t test is performed to determine the significance (*** P-values <0.001, ** P-
values <0.01, * P-values <0.05) 
 
3.4 Involvement of cancer stem cells in resistance to therapy and their specific 
targeting with salinomycin 
 
In addition to its association with poor prognosis and aggressiveness, HER2 protein 
has been associated with chemoresistance and cancer stem cells 55,106. As shown in 
previous results, mammospheres are enriched for cancer stem cells. Therefore, to 
identify the cancer stem cell populations, sorted cells were first subjected to analysis 
of stem cell markers. qPCR analysis of stem cell markers in these two fractions of 
MCF-7 2D cells, 24 h old mammospheres and 7 days old mammospheres 
demonstrated almost equal expression levels of NANOG, OCT4 and SOX2 in 2D as 
well as in the 24 h old mammospheres. In contrast, the mammospheres grown for 7 
days expressed 4.5 fold, 5 fold and 2.5 fold more NANOG, OCT4 and SOX2 
respectively in HER2low cells (Figure 19). Hence, a time-dependent upregulation of 
NOS markers in HER2low cells of the MCF-7 mammospheres was observed 
suggesting an evolution of these markers over time during the formation of 
mammospheres.  
Since there was an elevation of the stem cell markers in HER2low population of the 
mammospheres, stem cell like phenotype of this fraction was confirmed by 
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physiological assays. matrigel, HER2low population displayed presence of ductal-like 
outgrowths after 7 days (Figure 21 a). 
 
 
Figure 19. Expression of stem cell markers in HER2low and HER2high fraction of mammospheres.   
qPCR analysis of NANOG, OCT4 and SOX2 for HER2low and HER2high population sorted from MCF-7 
2D cells, mammospheres of MCF-7 grown for 24 h and 7 d. The graph shows expression levels of 
markers in the HER2low fraction normalized to expression levels in the HER2high fraction. 
 
Proliferation analysis of these two populations shown in Figure 20, exhibits slow 
proliferation of the HER2low cells in mammospheres of MCF-7. Additionally, the no. of 
colonies obtained with HER2low population in matrigel, was higher than that obtained 
from HER2high (Figure 21 b). This data suggests that the HER2low population 
manifests properties similar to stem cells or poorly differentiated cells such as slow 
proliferation, ductal-like outgrowth in matrigel and higher colony formation ability.  
 
 
Figure 20. Proliferation of HERlow and HER2high populations of MCF-7 MS. Growth curve of 
HER2high and HER2low sorted populations of MCF-7 mammospheres. Experiment was performed in 
triplicates (n=3).  
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HER2low HER2high 
 
 
b) 
 
Figure 21. Classification of stem cells in HER2low  cells using matrigel growth pattern.  (a) 
Matrigel outgrowths of HER2high and HER2low sorted populations of MCF-7 mammospheres. A section 
of 50µm is shown here. (b) The colonies formed in matrigel were counted manually after 7 d.  The 
experiment was performed in triplicates (n=3). Student’s t test was performed to determine the 
significance (*** P-values <0.001). 
 
 Further to confirm this observation in vivo, we injected HER2low and HER2high 
immunosorted cells from MCF-7 mammospheres subcutaneously in immunodeficient 
mice (performed by Florian Kopp). The take rate was similar for both the groups. 
However, monitoring the growth of these tumors over 145 days demonstrated that 
HER2low cell fraction formed visible tumors 6 weeks before tumors of HER2high cells 
(Figure 22). In accordance with Figure 20, tumors from HER2low cells demonstrated 
slow proliferation rate as compared to tumors from HER2high cells.  
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Figure 22. Growth curve of tumors from HER2low and HER2high sorted population injected in 
mice. Sorted HER2low and HER2high cells from 7 d old MCF-7 mammospheres were injected 
subcutaneously in the right flank of female immunodeficient mice (7 mice per group). For HER2low 
xenografts, 2 mice developed tumors and for HER2high xenografts 3 mice developed tumors. The 
growth curve calculated over 145 days after injection is shown here. 
 
HER2 expression in xenografts was performed by immunohistochemistry for the 
HER2 protein. HER2high tissue sections displayed some feebly expressed extra 
cellular HER2 while HER2low showed no expression of HER2 depicting the 
authenticity of the sorted cells. Moreover, the HER2low cryosections showed 
abundant expression of OCT4 while that of HER2high showed no expression (Figure 
23).  Besides, an upregulation in NANOG, OCT4 and SOX2 was seen at mRNA level 
too in xenografts of HER2low cells as compared to those of HER2high cells (Figure 24). 
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HER2low HER2high 
 
Figure 23. Immunohistochemical analysis of tissue sections obtained from tumors of sorted 
fractions of MCF-7 MS. Immunohistochemical analysis of cyosections of tumors from injected 
HER2low and HER2high cells stained with HER2 and OCT4 antibodies. An image taken with 40X 
objective is shown here with an enlarged section in lower left corner. A section of 50µm is shown here. 
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Figure 24. qPCR analysis of stem cell markers in tumors obtained by injection of sorted 
populations. qPCR analysis of tumors obtained from injection of HER2low and HER2high sorted 
populations in immuno-compromised mouse. The experiment is performed in triplicates (n=3).  
 
Further aim was to target specifically these two cell fractions HER2high and HER2low, 
i.e. cancer stem cells. On the one hand trastuzumab was used to treat the HER2high 
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subset as it is commonly used in clinics for treating HER2-positive breast cancer 
patients. On the other hand, Gupta et al. have recently found that salinomycin 
specifically kills the cancer stem cell population of tumors 110. Therefore we analyzed 
whether it is effective against the HER2low subset. As expected, HER2high cells 
exhibited a dose dependent response to trastuzumab. On the contrary, HER2low cells 
were unaffected by trastuzumab treatment. Salinomycin showed exactly the opposite 
effect as it killed HER2low cells in a dose dependent manner (Figure 25 a and b). 
Furthermore, the HER2low fraction was more resistant to the classical 
chemotherapeutic drug doxorubicin than the HER2high fraction (Figure 25 c). Thus, we 
authenticated our hypothesis that HER2low fraction constitutes cancer stem cells that 
are effectively killed by salinomycin.  
 
 
 
a) 
 
b) 
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Figure 25. Specific treatments of sorted populations. (a) HER2high and HER2low sorted cell 
populations of MCF-7 mammospheres were treated with trastuzumab (0.5µg/ml, 5µg/ml and 50µg/ml) 
for 7d. A cell viability assay was performed subsequently. (b) HER2high and HER2low sorted cell 
populations of MCF-7 mammospheres were treated with salinomycin (0.5µM, 0.25µM, 0.1µM) for 7 
days. A cell viability assay was performed subsequently. (c) Sorted HER2low and HER2high cells from 7 
day old MCF-7 mammospheres were treated with 1µM doxorubicin for 72 hrs. Cell viability was 
performed. All set of experiments were performed in triplicates (n=3). Student’s t test is performed to 
determine the significance (* P-values <0.05). 
 
Furthermore, to confirm the effect of salinomycin on cancer stem cells, quantification 
of SOX2 positive population was performed by flow cytometric analysis of MCF-7 
mammospheres were treated with salinomycin demonstrated decrease in SOX2 
positive fraction as compared mock treated (DMSO) and trastuzumab treated cells 
from mammospheres. These findings further verify the specific effect of salinomycin 
against cancer stem cells. On the contrary, trastuzumab treated cells showed an 
upregulation or equal expression of these markers (Figure 26 a and b). 
After manifesting the specific targeting of these two populations from 
mammospheres, the effect of combinatorial treatment of these two drugs on 
mammospheres was investigated. Treatment of MCF-7 mammospheres with a 
combination of trastuzumab and salinomycin demonstrated more cell death as 
compared to single treatments (Figure 27 a). 
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Figure 26. FACS analysis of SOX2 in MCF-7 mammospheres after treatment with trastuzumab 
and salinomycin.  (a) FACS analysis of marker SOX2 (Cy5 tagged secondary antibody) and HER2 
(Al-488 tagged secondary antibody) for mock treated (DMSO treated), trastuzumab treated (50µg/ml) 
and salinomycin treated (0.1µM and 0.25µM) MCF-7 mammosphere. Treatment was performed for 7 
days and experiment was done in triplicates (n=3). (b) Quantification of SOX2 positive fraction (Q1) is 
shown in the bar graph. Student’s t test is performed to determine the significance (* P-values <0.05). 
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To open up the scope of study, mammospheres of high HER2 expressing cell lines 
BT-474 and SKBR-3 were treated in the similar manner. The combination manifested 
significantly greater effect than single treatments in mammospheres of BT-474 but 
not in SKBR-3 where a higher dose of trastuzumab would be required for the same 
(Figure 27 b and c). As expected, no significant increase in cell death was observed 
in the HER2 negative cell line MDA MB-231 treated with trastuzumab and 
salinomycin individually and in combination (Figure 27 d). This data supports a novel 
treatment approach for HER2-positive tumors, which may constitute cancer stem 
cells in the HER2low fraction which are showing resistance to trastuzumab treatment.   
 
 
 
a) MCF-7 MS 
  
  
b) BT-474 MS 
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c) SKBR-3 MS 
 
     
d) MDA MB-231 MS 
 
Figure 27. Combinatorial treatment of mammospheres. (a) Cell viability assay of MCF-7 
mammospheres was performed after treatment with 50µg/ml trastuzumab and 0.5µM salinomycin 
individually and in combination. (b) and (c) BT-474 and SKBR-3 mammospheres were treated with 
100µg/ml trastuzumab, 0.5µM salinomycin individually and in combination followed by cell viability 
assay. (d) MDA MB-231 mammospheres were treated with 50µg/ml trastuzumab, 0.5µM salinomycin 
individually and in combination. Cell viability assay was performed to determine the effect. Tra 
represents trastuzumab treatment and Sal represents salinomycin treatment. All experiments were 
performed in triplicates (n=3). Student’s t test is performed to determine the significance (*** P-values 
<0.001, ** P-values <0.01, * P-values <0.05).  
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3.5 Salinomycin abates migration of mesenchymal-like breast cancer cells 
 
The discovery of salinomycin is based on a screen. Gupta et al. knocked down E-
cadherin from human mammary epithelial cells hence obtaining a cell type showing 
upregulation of vimentin. From the vimentin positive cells they further isolated CD44 
positive cells as cancer stem cells and a screen of several drugs was performed. 
Salinomycin was one of the drugs that showed maximum effect against this cancer 
stem cell population 110. Furthermore, Basu et al. showed in their study the efficacy of 
salinomycin on E-cadherin low/ vimentin positive mesenchymal-like cell population 
125. Hence in the current work the effect of salinomycin on the breast cancer cells 
showing mesenchymal traits was analyzed. To establish this study the epithelial cell 
line MCF-7 and the mesenchymal-like cell line MDA MB-436 were exploited. As 
expected classical chemotherapeutics like doxorubicin and paclitaxel were more 
effective against the epithelial cell line MCF-7 than against the mesenchymal MDA 
MB-436 (Figure 28 a and b). Likewise, MCF-7 was resistant and mesenchymal-like 
cell line MDA MB-436 was sensitive to salinomycin (Figure 28 c).  
 
 
 
a) 
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Figure 28. Effect of chemotherapeutics on breast cancer cell lines. (a) Effect of doxorubicin on 
MCF-7 and MDA MB-436. Treatment was performed for 72 hrs followed by cell viability assay. (b) and 
(c) Effect of paclitaxel and salinomycin respectively on MCF-7 and MDA MB-436. Treatment was 
performed for 72 h followed by cell viability assay. Experiment was performed in triplicates (n=3).  
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Since salinomycin demonstrated the elimination of mesenchymal-like cell line, it was 
intriguing for us to investigate its effect on migration of these cells which is one of the 
hallmarks of epithelial to mesenchymal transition (EMT).  A scratch assay of MDA 
RESULTS 
MB-436 cells was performed with or without doxorubicin/ salinomycin. For this assay, 
concentrations of doxorubicin and salinomycin displaying similar percentage of cell 
death (15-20% apoptosis) were selected (Figure 29 a).  Selecting these 
concentrations enabled to confirm that the effect on migration of cells was specific 
and not due to cell death. Figure 29 b displays the results after 0 h and 72 h of 
treatment. As expected the untreated sample showed migration of cells into the 
wound leading to wound closure. On the other hand doxorubicin treated cells also 
showed almost similar migration to untreated ones hence demonstrating induction of 
aggressiveness after treatment with doxorubicin. On the contrary, salinomycin 
treated cells showed no or negligible migration of cells leaving the wound open. 
Furthermore, calculation of the velocities of cells from the three samples showed 
significant reduction in velocities of cells treated with salinomycin as compared to 
untreated and doxorubicin treated cells (Figure 29 c).  The distance accumulated by 
cells treated with salinomycin was also significantly reduced as compared to 
untreated and doxorubicin treated cells (Figure 29 d).  
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Figure 29. Effect of chemotherapeutics migration of MDA MB-436 cells (scratch assay). (a) Cell 
viability of MDA MB-436 was performed for 72 hrs and concentrations of doxorubicin and salinomycin 
showing 15-20% apoptosis/cell death after 72 h were selected for scratch assay. (b) Phase contrast 
images of MDA MB-436 cells treated with doxorubicin (DXR) and salinomycin (Sal). An untreated set 
was also kept as control. Samples were treated immediately after a scratch was made and images 
were taken every 6 hrs. Images of 0 h and 72 h are shown here. A section of 50µm is shown. (c) 
velocity of 20 random cells (n=20) each sample was calculated. (d) Distance accumulated by 20 
random cells/sample (n=20) was also calculated. Student’s t test is performed to determine the 
significance (*** P-values <0.001). 
 
To confirm this observation, a transwell migration assay with MDA MB-436 was 
performed with or without doxorubicin/ salinomycin treatment. The concentrations of 
doxorubicin and salinomycin showing 10-15% of apoptosis or cell death in 18 h were 
selected for this assay for similar reasons mentioned in above paragraph (Figure 30 
a). As expected, cells treated with salinomycin showed significantly reduced transwell 
migration as compared to doxorubicin treated and untreated cells (Figure 30 b).  
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Figure 30. Effect of chemotherapeutics on the migration of MDA MB-436 cells in transwell 
assay. (a) Cell viability of MDA MB-436 was performed for 72 hrs and concentrations of doxorubicin 
and salinomycin showing 15-20% apoptosis/cell death after 18 hrs were selected for transwell 
migration assay. (b) A quantification of number of cells migrated through the transwell after treatment 
for 18 hrs is shown here. Experiment was performed in triplicates (n=3). Total 15 fields/ transwell were 
counted. Student’s t test is performed to determine the significance (*** P-values <0.001). 
 
Early stages of metastasis demonstrate the phenomenon of EMT that gives rise to 
mesenchymal-like migrating cells hence configuring a heterogeneous tumor. Since 
this heterogeneous tumor consist of both epithelial cells and mesenchymal-like cells, 
it is necessary to target both the population for complete eradication. The results till 
now display effective targeting of epithelial cells by classical chemotherapeutics like 
doxorubicin and mesenchymal-like cells by salinomycin. Therefore, the effectiveness 
of combination of both drugs in treatment of heterogeneous tumors was tested. An 
establishment of an artificial heterogeneous system was done for this study by mixing 
epithelial MCF-7 cells and mesenchymal-like MDA MB-436 cells in 1:1 ratio. Figure 
31 a shows a phase contrast image displaying both epithelial and mesenchymal 
morphologies in mixed culture. Red arrows show epithelial like morphology and white 
arrows demonstrate mesenchymal-like morphology. The samples were further 
stained for E-cadherin as well as vimentin. Figure 31 b shows presence of both E-
cadherin as well as vimentin positive cells in the mixed culture further confirming the 
heterogeneity.  
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Figure 31. Mixed culture of breast cancer cell lines to mimic early metastatic breast cancer 
model. (a) Phase contrast microscopic image of MCF-7 and MDA MB-436 cells mixed in 1:1 ratio. 
Red arrows display epithelial-like morphology and white arrows demonstrate mesenchymal-like 
morphology. A section of 50µm is shown here. (b) Laser scanning microscopic image of the mixed 
culture stained for E-cadherin (red) and vimentin (green). Nucleus is stained with DAPI (blue). A 
section of 20µm is shown here.  
 
Afterwards the effect of chemotherapeutics doxorubicin and salinomycin (individually 
or in combination) was tested on the established heterogeneous tumor mimic. 
According to results of Figure 32, there is a significant reduction in number of the 
cells treated with combination of the two drugs as compared to control, doxorubicin 
treated and salinomycin treated samples. Hence, the results show synergistic effect 
of the combination in treating the mimic of metastatic tumor as compared to the 
single drug treatment. These results open up a new direction for treatment of early 
metastatic heterogeneous breast cancers.  
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Figure 32 Combinatorial treatment of mimic of early metastatic breast cancer model.  (a) As a 
control MCF-7 and MDA MB-436 cells were treated with doxorubicin (DXR) and salinomycin (Sal) 
individually or in combination for 72 h and individual drugs. Concentration of drugs showing 20-25% 
cell death was selected. (b) The mixture of MCF-7 and MDA MB-436 cells discussed above was 
treated with doxorubicin (DXR) and salinomycin (Sal) individually or in combination for 72 h followed 
by cell viability assay. Experiment was performed in triplicates. Student’s t test is performed to 
determine the significance (*** P-values <0.001). 
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4. DISCUSSION 
 
4.1 Treatment of breast cancer cell lines with classical chemotherapeutics 
eventually generates chemoresistance 
 
Resistance to current chemotherapeutic agents account for the failure of the 
treatment in more than 90% of the patients especially with metastatic cancers 39. 
Once the treatment with anthracycline or taxane-based chemotherapy is performed, 
options are limited as the responses are generally low. Response rates generally 
range from 30% to 70% but the responses are often not durable, with 6 to 10 months 
as the time taken for progression 126,127. This resistance can be innate one i.e. the 
cells are resistant to the drugs prior to the treatment or it can be acquired over time 
128. A number of mechanisms lead to the chemoresistance. Few are the alterations in 
the drug pharmacokinetics and metabolism, modification in the genes and protein 
expressions e.g. overexpression of β-tubulin isotypes, and topoisomerase II 
mutations, drug compartmentalization in the cellular organelles, altered repair of drug 
induced DNA damage, changes in the apoptotic signaling pathways (for example, 
mutated p53), and expression of proteins directly affecting cellular drug transport 
(efflux pumps) 129,130. The heterogeneity of the cancer cells, coupled with their high 
mutation rate, contributes to rapid selection for the drug-resistant clones. To 
characterize this resistance, a ‘molecular evolution assay’ (MEA) was developed and 
utilized in this study (Figure 7). Breast cancer cell lines were treated with the classical 
chemotherapeutic doxorubicin in cycles. Cell resistant to doxorubicin were allowed to 
recover and were characterized. This assay aided in characterizing and monitoring 
the changes in the resistant cells at molecular levels hence characterizing the 
resistance. A subsequent resistance acquisition over the rounds of MEA was 
observed along with increase in ABC transporters indicated by side population 
(Figure 8 and 9). These observations over the course of the cell resistance to 
doxorubicin are in line with the studies showing involvement of ABC transporter 
proteins to pump out drugs like doxorubicin hence escaping the treatment 131-133.  
Furthermore, mammosphere generating ability of cells recovered from each round of 
MEA was analyzed. Only cells from R1 and R2 could form mammospheres with a 
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decreasing potential over the passages. The study by Dittmer et al. showed 
disruption of the intact spheroid structure after the introduction of human 
mesenchymal stem cells in MCF-7 mammospheres. Additionally, an increase in 
invasive properties of the cells was observed 134. Therefore, decrease in MFP could 
be correlated with the probable increase in invasive properties of resistant cells 
obtained over the rounds of MEA (Figure 10).  
This study demonstrates that the inheritance of chemoresistance is a gradual and 
eventual process. After exposure to stressful environment e.g. chemotherapeutics, 
genetically instable cancer cells undergo certain changes that could lead to more 
aggressive phenotype. 
 
4.2 Heterogeneity and chemoresistance in breast cancer can be explored 
utilizing mammospheres 
 
Anchorage independent spheroids grown in serum-free media procure the property 
of heterogeneity and are utilized extensively to study different populations within 
tumors and enrich the stem cell-like cell population 135-137. Many studies have shown 
the association of different markers with different populations in mammospheres 
proving their heterogeneity. Furthermore, dependency of some cells from 
mammospheres on extra cellular matrix (ECM) proteins for acquiring 3 dimensional 
forms further points towards the heterogeneity displayed by spheroid cultures 115. 
Similarly, the results of Figure 11 show mammospheres of breast cancer cell lines 
procuring different morphologies. More aggressive and metastatic cell lines like MDA 
MB-231, MDA MB-468, MDA MB-435 etc. showed aggregate like appearance of 
mammospheres. On the other hand, MCF-7 and BT-474 that are epithelial cells 
displayed tight spheroids. One explanation for this observation could be tight cell-cell 
contacts due to expression of E-cadherin protein in epithelial cells. This protein is 
responsible for strong cell-cell interactions hence giving rise to tight spheroids. On 
the other hand, invasive and metastatic cell line loose the expression of E-cadherin 
and hence are unable to form tight spheroids and in turn exhibit aggregates 121,122. 
Likewise, the results also establish decreasing mammosphere forming potential 
displayed by invasive and metastatic cell lines as compared to epithelial ones that 
retain more or less constant MFP (Figure 12). The only exception is MDA MB-435 
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that shows increasing MFP which can be explained by presence of lectins and 
antigens required for cell-stromal adhesion and promoting tumor growth and 
progression 138.  
Moreover a coalition between stem cell markers namely CD44+, ALDH1+, MUC1 etc. 
and mammospheres have been revealed 78,83,90,91. In support to this finding, the 
results of figure13 revealed an elevation in NANOG, OCT 4 and SOX 2 levels. Since, 
the presence of the stem cell-like population in the tumor leads to chemoresistance, 
the effect of classical chemotherapeutics on mammospheres was analyzed. The 
results in Figure 14 clarifies that mammospheres acquire the property of 
chemoresistance along with enrichment of stem cell-like cells. Furthermore, based on 
the results showing acquisition of stem cell markers and chemoresistance in 
mammospheres over a period of 7 days, a model to explain involvement of stem cell 
like cells in resistance can be put forward (Figure 33).  
 
 
Figure 33. Model depicting dedifferentiation of cells after chemotherapy. This model 
demonstrates acquisition of stem cell-like properties by cells in tumor after they are exposed to certain 
barriers as chemotherapy. These dedifferentiated cells then skip therapy and give rise to new tumors.  
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4.3 HER2 protein is elevated in mammospheres 
 
The EGFR family is one of the receptor tyrosine kinase families involved in the 
chemoresistance 139. Additionally, the difference between molecular signalling of 
HER2 protein in 2D cells as well as in mammospheres shows the flexibility of 
oncogene switching, which may play an important role in the development of drug 
resistance 123. Likewise, in this study elevated HER2 protein levels in 
mammospheres and xenografts from mammospheres injected in female 
immunodeficient mice was demonstrated compared to 2D cell lines and xenografts 
from 2D cells (Figure 15). Additionally, there was a differential expression of HER2 
within individual cells of mammospheres, which made it possible to sort for HER2high 
and HER2low populations. 
Furthermore, not all the mechanisms leading to resistance and the cancer 
progression are explored till date. Being a multistep complex phenomenon, a number 
of procedures are available for the detection of cancer progression. For this purpose, 
studies with the 3 dimensional culture systems are extensively used to understand 
pathways regulating glandular morphogenesis and the epithelial cancer development 
140. For the formation of these 3D anchorage independent spheroids, the cells must 
acquire anoikis resistance. Anoikis resistance is associated with many factors and its 
association with HER2 over expression is the latest highlight 141. HER2 mediated 
anoikis resistance can be correlated with increased Erk activation and decreased pro 
apoptotic protein Bim expression 142. Besides, a recent study demonstrated that 
integrin α5 is highly upregulated in the HER2 overexpressing 3D spheroids and is 
required for HER2 mediated anoikis resistance 124. Likewise, results of Figure 18 
demonstrate nearly 3-fold more mammospheres at passage 0 in HER2high sorted 
population from MCF-7 as compared to HER2low sorted cells that eventually showed 
decrease in MFP till passage 2. This data displays succumbing of HER2low cells to 
anoikis hence strongly indicating involvement of HER2 in anoikis resistance and 
formation of mammospheres. HER2 over expression in the spheroids and its 
association with anoikis resistance makes it a key player in detection of circulating 
tumors cells (CTCs) 143-146. Additionally, the interconnection between HER2 
overexpression and autophagy provides a perfect environment to circumvent 
trastuzumab therapy hence giving rise to therapy resistance 147. 
 
DISCUSSION 
 80
4.4 Combinatorial treatment with salinomycin and trastuzumab eradicates 
cancer stem cells and HER2 positive cells of mammospheres 
 
20-25% of the breast cancers show amplification of HER2 protein and this genomic 
alteration is predictive of a poor clinical outcome 54,148. This overexpression leads to 
the cancer progression, aggressiveness and chemoresistance in breast cancers 149. 
Moreover, HER2 amplification results in 50-100 fold increase in the receptors on the 
cancer cells as compared to normal cells therefore making it a prime target for 
therapies 150. Trastuzumab (Herceptin) is a humanized recombinant monoclonal 
antibody establishing a significant clinical treatment against HER2 positive breast 
cancers 151. Moreover, the primary adjuvant therapy for the HER2 positive cancers is 
treatment with trastuzumab which targets HER2. Although it is one of the most 
effective treatments in oncology, a significant number of patients show resistance to 
this treatment 59,152.  
Furthermore, a new concept of drug resistance is coming in limelight that describes 
affiliation of cancer stem cells or stem cell-like cells to chemoresistance. Studies 
show that the cancer stem cells from leukemia displayed the resistance to 
duanorubicin and Ara-C 153. Similarly cancer stem cells from breast, pancreas and 
colon cancer also show resistance to chemotherapeutics 68,154,155.  These findings 
indicate that the selection barriers conferring dedifferentiation of cells and 
heterogeneity of the tumors pave a way for escaping therapies. Hence, targeting 
cancer stem cells and subpopulations manifesting therapy resistance will achieve 
definitive curative benefits. Korkaya et al. in their study, revealed a correlation 
between HER2 gene amplification and the upregulation of stem cell markers 90. 
Moreover, a similar study displays effective targeting of tumor initiating cells (TICs) 
utilizing trastuzumab antibody 106. Since cancer stem cells or dedifferentiated cells 
are the future targets for effective therapies, elucidation of the cancer stem cell 
population from mammospheres was performed in this study. Figure 19 displays 
upregulation of stem cell markers in HER2low immunosorted population as compared 
to HER2high population. Comparison of this upregulation in 2D MCF-7 cells, 24 hrs 
old MCF-7 mammospheres and 7 days old mammospheres indicates a time 
dependent increase in stem cell markers in the HER2low population. This observation 
suggests an acquisition of stem cell like properties eventually over the time hence 
indicating a dedifferentiation process. Likewise, the results in Figures 20 and 21 
confirm the stem cell like behavior of HER2low cells. Furthermore, the tissue sections 
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of the xenografts from female immunodeficient mice developed from injection of 
HER2low cells showed augmented expression of NANOG, OCT4 and SOX2 as 
compared to xenografts of HER2high (Figure 23 and 24). Moreover, a recent study 
depicted that sorted CD44high/CD24low cells that are regarded as the stem cell fraction 
of the immunoselected MCF-7 cell line are enriched in HER2low cells. This also 
supports the fact that MCF-7 contains a cancer stem cell fraction that displays 
reduced HER2 expression 156. A recent study indicates the possibility of 
heterogeneous HER2 amplified tumors harbouring the HER2low CSCs 157. Hence, 
eradication of HER2 positive cells by trastuzumab could give rise to cancer stem 
cells expressing low or no HER2. Our finding therefore might explain the resistance 
of some HER2 positive tumors to trastuzumab therapies leading to poor prognosis in 
relapsed patients.  
One step forward in the treatment of the cancer stem cells was the discovery of 
salinomycin that significantly reduces cell viability of human breast cancer stem-cell-
like cells resistant to chemotherapeutic drugs such as paclitaxel, doxorubicin, 
actinomycin D and campthotecin 110. One of the most common mechanisms of the 
drug resistance by CSC is overexpression of ABC transporters. Salinomycin can 
overcome this ABC transporter mediated therapy and apoptosis resistance in human 
leukemia and breast cancer stem cell-like cells 158,159. The data in Figure 25 and 26 
supports the above findings. HER2high cells display resistance to salinomycin but as 
expected are susceptible to trastuzumab. On the other hand, HER2low cells i.e. stem 
cells that are resistant to trastuzumab could be targeted using salinomycin. 
Salinomycin also effectively reduced the SOX2 positive stem cell population from 
MCF-7 mammospheres supporting the specific targeting of cancer stem cells. Since 
specific targeting of two populations of mammospheres using trastuzumab and 
salinomycin individually was successful, it was intriguing to check the combinatorial 
treatment of these two drugs. The results of Figure 27 suggest an additive or 
synergistic effect of the combination trastuzumab and salinomycin in eradicating 
most of the cells from mammospheres. 
Keeping in mind that in past two decades more than 30 new anticancer drugs have 
been introduced, but survival rates have improved only marginally for many types of 
cancers including breast cancer, it is necessary to formulate new and efficient 
strategies of treatment 160.  To explore this field, a novel combinatorial treatment 
method that targets most of the cells of heterogeneous mammospheres is 
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demonstrated for the first time in this thesis (Figure 34). Hence, the results of in vitro 
experiments open up a new horizon for combinatorial therapy eradicating most of the 
cells and can be considered as a baseline to develop novel treatment strategies 
targeting different heterogeneous cell populations in breast tumors.  
 
 
Figure 34. Combinatorial treatment of mammospheres. This model shows a novel combinatorial 
treatment strategy targeting HER2low or cancer stem cells with salinomycin and HER2high population 
utiling trastuzumab.  
 
4.5   Salinomycin reduces migration and targets mesenchymal-like cell 
population of breast cancer cell lines 
 
The results from the previous section showed a potential of salinomycin in targeting 
the cancer stem cell population from mammospheres. Recently Basu et al. gave a 
new dimension to salinomycin treatment as they established its efficacy against 
mesenchymal-like cells from head and neck squamous cell carcinoma. These cells 
expressed vimentin and were E-cadherin low hence suggesting a new target 
population for salinomycin 125. Additionally, a recent publication determined potential 
of salinomycin as an antagonist to wnt signalling pathway, a key player in stem cell 
signalling and metastasis 161. Therefore, we scrutinized the effect of salinomycin on 
breast cancer cells that have undergone EMT and hence are an inherent cause of 
metastasis. Our results in Figure 29 denote the escape of mesenchymal-like MDA 
MB-436 cells from classical chemotherapeutic treatment which, in turn affects 
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epithelial cells MCF-7. On the other hand, salinomycin effectively targets 
mesenchymal-like cells.  
The effect of salinomycin on mesenchymal-like population of breast cancer provoked 
to check its efficacy in targeting one of the hallmarks of the process of EMT i.e. 
migration of the mesenchymal cells. In fact, salinomycin affected the migration of 
cells as compared to doxorubicin treated and untreated MDA MB-436 cells. 
Furthermore, salinomycin also reduced the velocity of migrating mesenchymal–like 
cells. On the other hand, doxorubicin that is frequently used clinical drug to treat 
breast cancer showed no significant effect against migration. Moreover, the migration 
of the cells treated with doxorubicin was equivalent to the migration of the cells in 
untreated sample (Figure 29 and 30).  These results are in accordance with a recent 
paper that shows treatment with salinomycin induces the E-cadherin expression in 
prostrate cancer cells and reduces their transwell migration 112. This data suggest 
that treatment of metastatic breast cancers with classical chemotherapeutic will not 
efficiently target the mesenchymal-like migrating cells causing metastasis but in turn 
will enhance the process. The migrating cells should be targeted for a complete cure 
and hence salinomycin could be used as a novel drug for treating the same.  
Furthermore, the metastatic tumor undergoes certain physiological changes and the 
key player in triggering this process is EMT. Consequently, this tumor comprises 
epithelial cells as well as mesenchymal-like cells. To mimic this condition, a mixture 
of MCF-7 cells and MDA MB-436 cells was performed in a 1:1 ratio. Since the 
classical chemotherapeutics target epithelial cells and salinomycin targets 
mesenchymal-like cells, a combination of both drugs is expected to augment the 
effect and kill most of the tumor cells. The results in Figure 32 manifest the same. 
The in vitro data of this section, exhibits a new and novel combinatorial treatment to 
target metastatic breast tumors consisting of epithelial as well as mesenchymal cells 
(Figure 35). These results pave a gateway for in vivo and clinical studies utilizing 
salinomycin as one of the drugs for combinatorial treatment.  
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Figure 35. Model depicting combinatorial treatment of early metastatic breast cancer cells. This 
model puts forward a combinatorial treatment of metastatic breast tumors. Salinomycin targets the 
mesenchymal-like cells from the metastasizing tumors and epithelial cells are targeted by classical 
chemotherapeutics like doxorubicin.   
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5. SUMMARY 
 
One of the reasons for the chemoresistance of breast tumors could be their great 
degree of heterogeneity as they are composed of various histological subtypes, have 
variable clinical manifestations and underlying molecular signatures. Cancer cells 
surviving the therapy and giving rise to new tumors also comprise of dedifferentiated 
cells or cancer stem cells with a more aggressive phenotype. The persistence of 
tumorigenic cancer stem cells in locally invasive and metastatic cancer is responsible 
for the relapse of the disease. Since most of the chemotherapeutics used now-a-
days target more differentiated and proliferating population, there is a need to 
discover and design novel improved treatment strategies targeting aggressive tumor 
initiating subpopulation. 
This study characterized the evolution of resistance to classical chemotherapeutics in 
breast cancer cell lines with respect to their chemosensitivity, upregulation of stem 
cell markers, mammosphere formation and side population characteristics. 
Furthermore, analysis of 3 dimensional cultures (mammospheres) confirmed the 
involvement of heterogeneity and dedifferentiated cancer stem cells, in acquiring the 
resistance to classical therapies. Upregulaton and differential expression of receptor 
tyrosin kinase HER2 in mammospheres enabled the FACS sorting into HER2high and 
HER2low population.  This in turn facilitated the identification of HER2low population as 
the cancer stem cell population showing resistance to classical trastuzumab 
(monoclonal antibody against HER2) treatment. Furthermore, HER2low cells 
remained unaffected to classical chemotherapeutic doxorubicin treatment suggesting 
their role in chemoresistance. However, eradication of this stem cell-like cell 
population was efficiently performed by the drug salinomycin. Its specificity was 
further verified by effective reduction the SOX2 (stem cell marker) subset after 
treatment of mammospheres. Additionally, the combination of two drugs trastuzumab 
targeting HER2high cells and salinomycin targeting HER2low cancer stem cells 
demonstrated abolishment of most of the tumorigenic cells from mammospheres.  
Furthermore, effect of salinomycin on mesenchymal-like subset from beast cancer 
was also studied. The data demonstrate specific killing of epithelial cells by 
doxorubicin and mesenchymal-like cells using salinomycin. Besides, salinomycin 
also controlled the migration (one of the hallmarks of EMT) of mesenchymal-like 
cells. In contrast, doxorubicin treatment led to increased migration displaying a more 
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aggressive phenotype after treatment suggesting a reason for chemoresistance of 
metastatic tumors. Additionally, the combinatorial treatment of salinomycin and 
doxorubicin was superior to the individual treatment of an in vitro mimic of metastatic 
breast cancer.   
To summarize, this study puts forward new approaches of combinatorial treatments 
eradicating the tumor initiating cells from the heterogenic breast tumor models 
(mammospheres and epithelial-mesenchymal cell mixture). It also demonstrates the 
effect of salinomycin as an eliminator of resistant tumor subpopulations in vitro. 
Furthermore, in vivo and clinical studies need to be performed to validate its 
specificity, toxicity and efficacy as a potential drug. Likewise, studies on dosage, 
specific targeting and less toxic analogues of salinomycin should be accomplished 
for its approval in clinical usage. However, these findings pave the way to novel 
therapeutic strategies targeting most of the cells from heterogeneous breast tumors. 
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6 APPENDIX  
 
6.1 Appendix 1: Abbreviations 
 
5FU    5- Fluorouracil 
ADH    Atypical ductal hyperplasia 
ALDH1   Aldehyde dehydrogenase 1 
ALH    Atypical lobular hyperplasia 
cDNA     Complementary DNA 
CSCs    Cancer stem cells 
CTCs    Circulating tumor cells 
DAPI    4′,6-Diamidin-2-phenylindol 
DCIS    Ductal carcinoma in situ 
DDR1    Discoidin domain receptor 1 
DMSO    Dimethyl sulfoxide 
DNA     Deoxyribonucleic acid 
DXR    Doxorubicin 
ECM    Extra cellular matrix 
EDTA    Ethylenediaminetetraacetic acid 
EMT    Epithelial to mesenchymal transition 
ER    Estrogen receptor 
FACS    Fluorescent antibody cell sorter 
FBS     Fetal bovine serum 
GAPDH    Glyceraldehyde-3-phosphate dehydrogenase 
HEPES  N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid) 
HER2    Human Epidermal growth factor receptor 
IAP    Inhibitor of apoptosis protein 
IBC    Inflammatory breast disease 
IDC    Invasive ductal carcinoma 
ILC    Invasive lobular carcinoma 
LCIS    Lobular carcinoma in situ 
LSM    Laser scanning microscope 
MBC    Metastatic breast cancer 
APPENDIX 
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MEA    Molecular evolution assay 
MET    Mesenchymal to epithelial transition 
MFP    Mammosphere forming potential 
mRNA    Messenger RNA 
MS    Mammospheres 
NOS    NANOG, OCT4, SOX2 
P0, P1, P2   Passage 0, 1, 2 
PCR     Polymerase chain reaction 
PolyHEMA   Poly-2-hydroxyethyl methacrylate 
R1, R2, R3, R4  Round 1, 2, 3, 4 
RNA     Ribonucleic acid 
ROS    Reactive oxygen species 
RTKs    Receptor tyrosine kinases 
Sal    Salinomycin 
SP    Side population 
Tax    Paclitaxel 
Tra    Trastuzumab 
VEGF    Vascular endothelial growth factor 
XIAP    X-linked IAP 
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6.2 Appendix 2: Formulation of solutions 
 
DMEM media for SP  DMEM + 2% FBS + 10mM HEPES 
PBS solution for SP  1X PBS + 2% FBS + 10mM HEPES 
Permeabilization solution 0.2% Triton X 100 in 1X PBS 
Blocking solution 10% FCS + 1% Gelatin + 0.05% Triton X 100 in 1X PBS 
 
6.3 Appendix 3: Publications 
 
A. Poster Presentations 
Prajakta S. Oak, Florian Kopp, Chitra Thakur, Joachim Ellwart, Ulf R. Rapp, 
Axel Ullrich, Ernst Wagner, Pjotr Knyazev and Andreas Roidl: Salinomycin as 
an effective drug in combinatorial treatment of breast carcinoma. ABSTRACT 
in AACR special conference on “Advances in breast cancer research: 
Genetics, Biology and Clinical applications”, 12-15 Oct 2011, San 
Francisco, CA, USA. 
 
B. Publications 
i) Prajakta S. Oak, Florian Kopp, Chitra Thakur, Joachim W. Ellwart, Ulf R. 
Rapp, Axel Ullrich, Ernst Wagner, Pjotr Knyazev and Andreas Roidl: 
Combinatorial treatment of mammospheres with trastuzumab and salinomycin 
efficiently eradicates HER2-positive cancer cells and cancer stem cells. In 
Press. 
 
ii) Prajakta S. Oak, Florian Kopp, Chitra Thakur, Axel Ullrich, Pjotr Knyazev,  Ulf 
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